{
  "doc_id": "15",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识",
          "start_idx": 0,
          "end_idx": 31,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T1",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2
            },
            {
              "entity_id": "T2",
              "entity": "动脉粥样硬化性心血管疾病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 19
            },
            {
              "entity_id": "T3",
              "entity": "动脉",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 9
            },
            {
              "entity_id": "T4",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 17
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R0",
              "head_entity_id": "T1",
              "tail_entity_id": "T0"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R1",
              "head_entity_id": "T3",
              "tail_entity_id": "T2"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R2",
              "head_entity_id": "T4",
              "tail_entity_id": "T2"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "1",
      "paragraph": "随着经济高速发展、生活方式改变及人口老龄化，我国糖尿病患病率呈快速上升趋势。2007~2008年流行病学调查显示，我国20岁以上成人糖尿病患病率为9.7%。2010年流行病学调查显示，我国18岁以上成人糖尿病患病率为11.6%。在我国糖尿病患者中，90%以上为2型糖尿病(T2DM)。动脉粥样硬化性心血管疾病(ASCVD)包括冠心病、缺血性卒中及外周动脉疾病。T2DM与ASCVD关系密切，两者共存可进一步增加心血管事件和死亡风险，半数以上糖尿病患者的死亡与ASCVD相关。近年来，随着临床研究证据的不断积累和更新，关于降糖药物与T2DM患者心血管结局之间的关系也日益明确。因此，合理规范应用降糖药物对于T2DM合并ASCVD患者显得尤为重要。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "随着经济高速发展、生活方式改变及人口老龄化，我国糖尿病患病率呈快速上升趋势。2007~2008年流行病学调查显示，我国20岁以上成人糖尿病患病率为9.7%。2010年流行病学调查显示，我国18岁以上成人糖尿病患病率为11.6%。在我国糖尿病患者中，90%以上为2型糖尿病(T2DM)。动脉粥样硬化性心血管疾病(ASCVD)包括冠心病、缺血性卒中及外周动脉疾病。T2DM与ASCVD关系密切，两者共存可进一步增加心血管事件和死亡风险，半数以上糖尿病患者的死亡与ASCVD相关。近年来，随着临床研究证据的不断积累和更新，关于降糖药物与T2DM患者心血管结局之间的关系也日益明确。因此，合理规范应用降糖药物对于T2DM合并ASCVD患者显得尤为重要。",
          "start_idx": 0,
          "end_idx": 322,
          "entities": [
            {
              "entity_id": "T5",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 27
            },
            {
              "entity_id": "T6",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 69
            },
            {
              "entity_id": "T7",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 104
            },
            {
              "entity_id": "T8",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 120
            },
            {
              "entity_id": "T9",
              "entity": "2型糖尿病(T2DM)",
              "entity_type": "Disease",
              "start_idx": 130,
              "end_idx": 141
            },
            {
              "entity_id": "T10",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 130,
              "end_idx": 132
            },
            {
              "entity_id": "T11",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 136,
              "end_idx": 138
            },
            {
              "entity_id": "T12",
              "entity": "动脉粥样硬化性心血管疾病(ASCVD)",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 161
            },
            {
              "entity_id": "T13",
              "entity": "动脉",
              "entity_type": "Anatomy",
              "start_idx": 142,
              "end_idx": 144
            },
            {
              "entity_id": "T14",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 149,
              "end_idx": 152
            },
            {
              "entity_id": "T15",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 163,
              "end_idx": 166
            },
            {
              "entity_id": "T16",
              "entity": "缺血性卒中",
              "entity_type": "Disease",
              "start_idx": 167,
              "end_idx": 172
            },
            {
              "entity_id": "T17",
              "entity": "外周动脉疾病",
              "entity_type": "Disease",
              "start_idx": 173,
              "end_idx": 179
            },
            {
              "entity_id": "T18",
              "entity": "外周动脉",
              "entity_type": "Anatomy",
              "start_idx": 173,
              "end_idx": 177
            },
            {
              "entity_id": "T19",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 180,
              "end_idx": 184
            },
            {
              "entity_id": "T20",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 180,
              "end_idx": 182
            },
            {
              "entity_id": "T21",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 185,
              "end_idx": 190
            },
            {
              "entity_id": "T22",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 220,
              "end_idx": 223
            },
            {
              "entity_id": "T23",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 229,
              "end_idx": 234
            },
            {
              "entity_id": "T24",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 265,
              "end_idx": 269
            },
            {
              "entity_id": "T25",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 265,
              "end_idx": 267
            },
            {
              "entity_id": "T26",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 302,
              "end_idx": 306
            },
            {
              "entity_id": "T27",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 302,
              "end_idx": 304
            },
            {
              "entity_id": "T28",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 308,
              "end_idx": 313
            },
            {
              "entity_id": "T29",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 205,
              "end_idx": 210
            },
            {
              "entity_id": "T30",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 205,
              "end_idx": 208
            },
            {
              "entity_id": "T31",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 271,
              "end_idx": 274
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R3",
              "head_entity_id": "T10",
              "tail_entity_id": "T9"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R4",
              "head_entity_id": "T11",
              "tail_entity_id": "T9"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R5",
              "head_entity_id": "T13",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R6",
              "head_entity_id": "T14",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R7",
              "head_entity_id": "T18",
              "tail_entity_id": "T17"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R8",
              "head_entity_id": "T20",
              "tail_entity_id": "T19"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R9",
              "head_entity_id": "T25",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R10",
              "head_entity_id": "T31",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R11",
              "head_entity_id": "T27",
              "tail_entity_id": "T26"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R12",
              "head_entity_id": "T30",
              "tail_entity_id": "T29"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "2",
      "paragraph": "为了指导我国临床医师对T2DM合并ASCVD患者进行规范化管理，并且充分了解T2DM合并ASCVD患者的综合管理策略、降糖治疗原则、血糖控制目标及常用降糖药物合理应用，由我国内分泌科、心内科、肾内科及临床流行病学专家联合制定了本共识。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "为了指导我国临床医师对T2DM合并ASCVD患者进行规范化管理，并且充分了解T2DM合并ASCVD患者的综合管理策略、降糖治疗原则、血糖控制目标及常用降糖药物合理应用，由我国内分泌科、心内科、肾内科及临床流行病学专家联合制定了本共识。",
          "start_idx": 0,
          "end_idx": 117,
          "entities": [
            {
              "entity_id": "T32",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 15
            },
            {
              "entity_id": "T33",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 11,
              "end_idx": 13
            },
            {
              "entity_id": "T34",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 22
            },
            {
              "entity_id": "T35",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 42
            },
            {
              "entity_id": "T36",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 38,
              "end_idx": 40
            },
            {
              "entity_id": "T37",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 49
            },
            {
              "entity_id": "T38",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 66,
              "end_idx": 68
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R13",
              "head_entity_id": "T33",
              "tail_entity_id": "T32"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R14",
              "head_entity_id": "T36",
              "tail_entity_id": "T35"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R15",
              "head_entity_id": "T38",
              "tail_entity_id": "T35"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R16",
              "head_entity_id": "T38",
              "tail_entity_id": "T37"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "3",
      "paragraph": "一、T2DM合并ASCVD的流行病学",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、T2DM合并ASCVD的流行病学",
          "start_idx": 0,
          "end_idx": 18,
          "entities": [
            {
              "entity_id": "T39",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T40",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4
            },
            {
              "entity_id": "T41",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R17",
              "head_entity_id": "T40",
              "tail_entity_id": "T39"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "4",
      "paragraph": "2006年中国心脏调查发现，52.9%的冠心病住院患者合并糖尿病。另一方面，在全国三甲医院住院T2DM患者中，17.1%合并心血管疾病，13.2%合并脑血管疾病。在我国大型城市住院T2DM患者中，25.1%合并冠心病，17.3%合并脑血管疾病。中国“3B”研究显示，门诊就诊的T2DM患者中，14.6%合并心血管疾病，10.1%合并包括缺血性卒中在内的脑血管疾病。上述研究数据表明，我国T2DM患者合并ASCVD的情况非常普遍，已日益成为糖尿病管理的一个巨大挑战，值得临床医生给予高度重视。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2006年中国心脏调查发现，52.9%的冠心病住院患者合并糖尿病。另一方面，在全国三甲医院住院T2DM患者中，17.1%合并心血管疾病，13.2%合并脑血管疾病。",
          "start_idx": 0,
          "end_idx": 81,
          "entities": [
            {
              "entity_id": "T42",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23
            },
            {
              "entity_id": "T43",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 32
            },
            {
              "entity_id": "T44",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 51
            },
            {
              "entity_id": "T45",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 47,
              "end_idx": 49
            },
            {
              "entity_id": "T50",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 67
            },
            {
              "entity_id": "T51",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 62,
              "end_idx": 65
            },
            {
              "entity_id": "T52",
              "entity": "脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 80
            },
            {
              "entity_id": "T53",
              "entity": "脑血管",
              "entity_type": "Anatomy",
              "start_idx": 75,
              "end_idx": 78
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R18",
              "head_entity_id": "T45",
              "tail_entity_id": "T44"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R21",
              "head_entity_id": "T51",
              "tail_entity_id": "T50"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R22",
              "head_entity_id": "T53",
              "tail_entity_id": "T52"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "在我国大型城市住院T2DM患者中，25.1%合并冠心病，17.3%合并脑血管疾病。",
          "start_idx": 81,
          "end_idx": 122,
          "entities": [
            {
              "entity_id": "T54",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 13
            },
            {
              "entity_id": "T55",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 9,
              "end_idx": 11
            },
            {
              "entity_id": "T56",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 27
            },
            {
              "entity_id": "T57",
              "entity": "脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 40
            },
            {
              "entity_id": "T58",
              "entity": "脑血管",
              "entity_type": "Anatomy",
              "start_idx": 35,
              "end_idx": 38
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R23",
              "head_entity_id": "T55",
              "tail_entity_id": "T54"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R24",
              "head_entity_id": "T58",
              "tail_entity_id": "T57"
            }
          ]
        },
        {
          "sentence_id": "2",
          "sentence": "中国“3B”研究显示，门诊就诊的T2DM患者中，14.6%合并心血管疾病，10.1%合并包括缺血性卒中在内的脑血管疾病。",
          "start_idx": 122,
          "end_idx": 182,
          "entities": [
            {
              "entity_id": "T46",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 20
            },
            {
              "entity_id": "T47",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 16,
              "end_idx": 18
            },
            {
              "entity_id": "T59",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 36
            },
            {
              "entity_id": "T60",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 31,
              "end_idx": 34
            },
            {
              "entity_id": "T61",
              "entity": "缺血性卒中",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 51
            },
            {
              "entity_id": "T62",
              "entity": "脑血管疾病",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 59
            },
            {
              "entity_id": "T63",
              "entity": "脑血管",
              "entity_type": "Anatomy",
              "start_idx": 54,
              "end_idx": 57
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R19",
              "head_entity_id": "T47",
              "tail_entity_id": "T46"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R25",
              "head_entity_id": "T60",
              "tail_entity_id": "T59"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R26",
              "head_entity_id": "T63",
              "tail_entity_id": "T62"
            }
          ]
        },
        {
          "sentence_id": "3",
          "sentence": "上述研究数据表明，我国T2DM患者合并ASCVD的情况非常普遍，已日益成为糖尿病管理的一个巨大挑战，值得临床医生给予高度重视。",
          "start_idx": 182,
          "end_idx": 245,
          "entities": [
            {
              "entity_id": "T48",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 15
            },
            {
              "entity_id": "T49",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 11,
              "end_idx": 13
            },
            {
              "entity_id": "T64",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 24
            },
            {
              "entity_id": "T65",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 40
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R20",
              "head_entity_id": "T49",
              "tail_entity_id": "T48"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "5",
      "paragraph": "二、T2DM患者中ASCVD危险因素的综合管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、T2DM患者中ASCVD危险因素的综合管理",
          "start_idx": 0,
          "end_idx": 23,
          "entities": [
            {
              "entity_id": "T66",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T67",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4
            },
            {
              "entity_id": "T68",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R27",
              "head_entity_id": "T67",
              "tail_entity_id": "T66"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "6",
      "paragraph": "除高血糖外，T2DM患者往往合并有高血压、血脂异常、肥胖等多重心血管危险因素。因此，对于大多数T2DM患者，特别是合并ASCVD的患者，应采取综合管理策略，在控制血糖的同时，全面管理好各种心血管危险因素，具体措施包括生活方式干预、降压、调脂、抗血小板治疗、减重等，以期最大程度降低心血管事件和死亡风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "除高血糖外，T2DM患者往往合并有高血压、血脂异常、肥胖等多重心血管危险因素。因此，对于大多数T2DM患者，特别是合并ASCVD的患者，应采取综合管理策略，在控制血糖的同时，全面管理好各种心血管危险因素，具体措施包括生活方式干预、降压、调脂、抗血小板治疗、减重等，以期最大程度降低心血管事件和死亡风险。",
          "start_idx": 0,
          "end_idx": 151,
          "entities": [
            {
              "entity_id": "T69",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10
            },
            {
              "entity_id": "T70",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8
            },
            {
              "entity_id": "T71",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 20
            },
            {
              "entity_id": "T72",
              "entity": "血脂异常",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 25
            },
            {
              "entity_id": "T73",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 28
            },
            {
              "entity_id": "T74",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 51
            },
            {
              "entity_id": "T75",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 47,
              "end_idx": 49
            },
            {
              "entity_id": "T76",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 64
            },
            {
              "entity_id": "T77",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 81,
              "end_idx": 83
            },
            {
              "entity_id": "T78",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 108,
              "end_idx": 114
            },
            {
              "entity_id": "T79",
              "entity": "降压",
              "entity_type": "Treatment",
              "start_idx": 115,
              "end_idx": 117
            },
            {
              "entity_id": "T80",
              "entity": "调脂",
              "entity_type": "Treatment",
              "start_idx": 118,
              "end_idx": 120
            },
            {
              "entity_id": "T81",
              "entity": "抗血小板治疗",
              "entity_type": "Treatment",
              "start_idx": 121,
              "end_idx": 127
            },
            {
              "entity_id": "T82",
              "entity": "减重",
              "entity_type": "Treatment",
              "start_idx": 128,
              "end_idx": 130
            },
            {
              "entity_id": "T83",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 140,
              "end_idx": 145
            },
            {
              "entity_id": "T84",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 140,
              "end_idx": 143
            },
            {
              "entity_id": "T85",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 4
            },
            {
              "entity_id": "T86",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 31,
              "end_idx": 34
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R28",
              "head_entity_id": "T70",
              "tail_entity_id": "T69"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R29",
              "head_entity_id": "T86",
              "tail_entity_id": "T69"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R30",
              "head_entity_id": "T75",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R31",
              "head_entity_id": "T77",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R32",
              "head_entity_id": "T77",
              "tail_entity_id": "T76"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R33",
              "head_entity_id": "T84",
              "tail_entity_id": "T83"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "7",
      "paragraph": "(一)生活方式干预",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(一)生活方式干预",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T87",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 3,
              "end_idx": 9
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "8",
      "paragraph": "对于所有T2DM合并ASCVD患者，生活方式干预应作为综合管理策略的基础性措施，并贯穿于综合治疗的全过程。生活方式干预包括健康教育、戒烟限酒、限盐(<6g/d)、合理饮食、规律运动、注意保持心理平衡等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于所有T2DM合并ASCVD患者，生活方式干预应作为综合管理策略的基础性措施，并贯穿于综合治疗的全过程。",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T88",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 8
            },
            {
              "entity_id": "T89",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 4,
              "end_idx": 6
            },
            {
              "entity_id": "T90",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 15
            },
            {
              "entity_id": "T91",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 18,
              "end_idx": 24
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R34",
              "head_entity_id": "T89",
              "tail_entity_id": "T88"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R35",
              "head_entity_id": "T91",
              "tail_entity_id": "T88"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R36",
              "head_entity_id": "T91",
              "tail_entity_id": "T90"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "生活方式干预包括健康教育、戒烟限酒、限盐(<6g/d)、合理饮食、规律运动、注意保持心理平衡等。",
          "start_idx": 53,
          "end_idx": 101,
          "entities": [
            {
              "entity_id": "T92",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 0,
              "end_idx": 6
            },
            {
              "entity_id": "T93",
              "entity": "健康教育",
              "entity_type": "Treatment",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T94",
              "entity": "戒烟",
              "entity_type": "Treatment",
              "start_idx": 13,
              "end_idx": 15
            },
            {
              "entity_id": "T95",
              "entity": "合理饮食",
              "entity_type": "Treatment",
              "start_idx": 28,
              "end_idx": 32
            },
            {
              "entity_id": "T96",
              "entity": "规律运动",
              "entity_type": "Treatment",
              "start_idx": 33,
              "end_idx": 37
            },
            {
              "entity_id": "T97",
              "entity": "注意保持心理平衡",
              "entity_type": "Treatment",
              "start_idx": 38,
              "end_idx": 46
            },
            {
              "entity_id": "T98",
              "entity": "限盐(<6g/d)",
              "entity_type": "Treatment",
              "start_idx": 18,
              "end_idx": 27
            },
            {
              "entity_id": "T99",
              "entity": "限酒",
              "entity_type": "Treatment",
              "start_idx": 15,
              "end_idx": 17
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "9",
      "paragraph": "(二)降压治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(二)降压治疗",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "10",
      "paragraph": "高血压与高血糖并存可使ASCVD发生和发展风险显著增加，从而增加T2DM患者的病死率。研究显示，控制高血压可显著降低ASCVD发生和发展的风险，降压治疗的心血管获益主要源自血压控制本身。因此，对于大多数T2DM合并高血压患者，血压控制目标为<140/80mmHg；对于年轻、没有并发症、合并白蛋白尿或糖尿病慢性肾脏病(CKD)患者，可将收缩压控制在<130mmHg。选择降压药物时，应综合考虑疗效、心肾保护作用、安全性、依从性、对代谢的影响等因素。大多数患者需要至少两种不同作用机制的降压药物的联合治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "高血压与高血糖并存可使ASCVD发生和发展风险显著增加，从而增加T2DM患者的病死率。研究显示，控制高血压可显著降低ASCVD发生和发展的风险，降压治疗的心血管获益主要源自血压控制本身。因此，对于大多数T2DM合并高血压患者，血压控制目标为<140/80mmHg；对于年轻、没有并发症、合并白蛋白尿或糖尿病慢性肾脏病(CKD)患者，可将收缩压控制在<130mmHg。",
          "start_idx": 0,
          "end_idx": 183,
          "entities": [
            {
              "entity_id": "T100",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3
            },
            {
              "entity_id": "T101",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7
            },
            {
              "entity_id": "T102",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16
            },
            {
              "entity_id": "T103",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 36
            },
            {
              "entity_id": "T104",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34
            },
            {
              "entity_id": "T105",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 53
            },
            {
              "entity_id": "T106",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 63
            },
            {
              "entity_id": "T107",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 105
            },
            {
              "entity_id": "T108",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 101,
              "end_idx": 103
            },
            {
              "entity_id": "T109",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 110
            },
            {
              "entity_id": "T110",
              "entity": "<140/80mmHg",
              "entity_type": "Test_Value",
              "start_idx": 120,
              "end_idx": 131
            },
            {
              "entity_id": "T111",
              "entity": "白蛋白尿",
              "entity_type": "Disease",
              "start_idx": 145,
              "end_idx": 149
            },
            {
              "entity_id": "T112",
              "entity": "糖尿病慢性肾脏病(CKD)",
              "entity_type": "Disease",
              "start_idx": 150,
              "end_idx": 163
            },
            {
              "entity_id": "T113",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 86,
              "end_idx": 88
            },
            {
              "entity_id": "T114",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 113,
              "end_idx": 115
            },
            {
              "entity_id": "T115",
              "entity": "收缩压",
              "entity_type": "Test",
              "start_idx": 168,
              "end_idx": 171
            },
            {
              "entity_id": "T116",
              "entity": "<130mmHg",
              "entity_type": "Test_Value",
              "start_idx": 174,
              "end_idx": 182
            },
            {
              "entity_id": "T117",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 155,
              "end_idx": 157
            },
            {
              "entity_id": "T118",
              "entity": "慢性",
              "entity_type": "Class",
              "start_idx": 153,
              "end_idx": 155
            },
            {
              "entity_id": "T119",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 77,
              "end_idx": 80
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R37",
              "head_entity_id": "T104",
              "tail_entity_id": "T103"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R38",
              "head_entity_id": "T119",
              "tail_entity_id": "T105"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R39",
              "head_entity_id": "T113",
              "tail_entity_id": "T105"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R40",
              "head_entity_id": "T108",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R41",
              "head_entity_id": "T114",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R42",
              "head_entity_id": "T114",
              "tail_entity_id": "T109"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R43",
              "head_entity_id": "T115",
              "tail_entity_id": "T111"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R44",
              "head_entity_id": "T115",
              "tail_entity_id": "T112"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R45",
              "head_entity_id": "T117",
              "tail_entity_id": "T112"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R46",
              "head_entity_id": "T118",
              "tail_entity_id": "T112"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "选择降压药物时，应综合考虑疗效、心肾保护作用、安全性、依从性、对代谢的影响等因素。",
          "start_idx": 183,
          "end_idx": 224,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "大多数患者需要至少两种不同作用机制的降压药物的联合治疗。",
          "start_idx": 224,
          "end_idx": 252,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "11",
      "paragraph": "(三)调脂治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(三)调脂治疗",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "12",
      "paragraph": "T2DM患者通常合并多项血脂异常，主要表现为TG升高、LDL-C升高及HDL-C降低、三者均与T2DM患者ASCVD发生风险增高相关。T2DM合并ASCVD患者属于极高危人群，调脂治疗的首要干预靶点IDL-C目标值为<1.8mmol/L，次要干预靶点非HDL-C目标值为<2.6mmol/L，为了达到上述目标-应首选他汀类药物。经他汀类治疗后，如非HDL-C仍不能达到目标值.可在他汀类基础上加用贝特类、高纯度鱼油制剂。对于严重高TG血症(空腹TG≥5.7mmol/L)患者，应首先考虑使用贝特类、高纯度鱼油制剂或烟酸类药物治疗，以预防急性胰腺炎的发生。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "T2DM患者通常合并多项血脂异常，主要表现为TG升高、LDL-C升高及HDL-C降低、三者均与T2DM患者ASCVD发生风险增高相关。T2DM合并ASCVD患者属于极高危人群，调脂治疗的首要干预靶点IDL-C目标值为<1.8mmol/L，次要干预靶点非HDL-C目标值为<2.6mmol/L，为了达到上述目标-应首选他汀类药物。经他汀类治疗后，如非HDL-C仍不能达到目标值.可在他汀类基础上加用贝特类、高纯度鱼油制剂。对于严重高TG血症(空腹TG≥5.7mmol/L)患者，应首先考虑使用贝特类、高纯度鱼油制剂或烟酸类药物治疗，以预防急性胰腺炎的发生。",
          "start_idx": 0,
          "end_idx": 277,
          "entities": [
            {
              "entity_id": "T120",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T121",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2
            },
            {
              "entity_id": "T122",
              "entity": "血脂异常",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 16
            },
            {
              "entity_id": "T123",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 24
            },
            {
              "entity_id": "T124",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 32
            },
            {
              "entity_id": "T125",
              "entity": "HDL-C",
              "entity_type": "Test_items",
              "start_idx": 35,
              "end_idx": 40
            },
            {
              "entity_id": "T126",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 24,
              "end_idx": 26
            },
            {
              "entity_id": "T127",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 32,
              "end_idx": 34
            },
            {
              "entity_id": "T128",
              "entity": "降低",
              "entity_type": "Test_Value",
              "start_idx": 40,
              "end_idx": 42
            },
            {
              "entity_id": "T129",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 51
            },
            {
              "entity_id": "T130",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 47,
              "end_idx": 49
            },
            {
              "entity_id": "T131",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 58
            },
            {
              "entity_id": "T132",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 67,
              "end_idx": 71
            },
            {
              "entity_id": "T133",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 67,
              "end_idx": 69
            },
            {
              "entity_id": "T134",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 73,
              "end_idx": 78
            },
            {
              "entity_id": "T135",
              "entity": "IDL-C",
              "entity_type": "Test_items",
              "start_idx": 99,
              "end_idx": 104
            },
            {
              "entity_id": "T136",
              "entity": "<1.8mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 108,
              "end_idx": 118
            },
            {
              "entity_id": "T137",
              "entity": "非HDL-C",
              "entity_type": "Test_items",
              "start_idx": 125,
              "end_idx": 131
            },
            {
              "entity_id": "T138",
              "entity": "<2.6mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 135,
              "end_idx": 145
            },
            {
              "entity_id": "T139",
              "entity": "他汀类药物",
              "entity_type": "Drug",
              "start_idx": 158,
              "end_idx": 163
            },
            {
              "entity_id": "T140",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 165,
              "end_idx": 168
            },
            {
              "entity_id": "T141",
              "entity": "非HDL-C",
              "entity_type": "Test_items",
              "start_idx": 173,
              "end_idx": 179
            },
            {
              "entity_id": "T142",
              "entity": "不能达到目标值",
              "entity_type": "Test_Value",
              "start_idx": 180,
              "end_idx": 187
            },
            {
              "entity_id": "T143",
              "entity": "他汀类",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 193
            },
            {
              "entity_id": "T144",
              "entity": "贝特类",
              "entity_type": "Drug",
              "start_idx": 198,
              "end_idx": 201
            },
            {
              "entity_id": "T145",
              "entity": "高纯度鱼油制剂",
              "entity_type": "Drug",
              "start_idx": 202,
              "end_idx": 209
            },
            {
              "entity_id": "T146",
              "entity": "高TG血症",
              "entity_type": "Disease",
              "start_idx": 214,
              "end_idx": 219
            },
            {
              "entity_id": "T147",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 212,
              "end_idx": 214
            },
            {
              "entity_id": "T148",
              "entity": "空腹TG",
              "entity_type": "Test_items",
              "start_idx": 220,
              "end_idx": 224
            },
            {
              "entity_id": "T149",
              "entity": "≥5.7mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 224,
              "end_idx": 234
            },
            {
              "entity_id": "T150",
              "entity": "贝特类",
              "entity_type": "Drug",
              "start_idx": 245,
              "end_idx": 248
            },
            {
              "entity_id": "T151",
              "entity": "高纯度鱼油制剂",
              "entity_type": "Drug",
              "start_idx": 249,
              "end_idx": 256
            },
            {
              "entity_id": "T152",
              "entity": "烟酸类药物",
              "entity_type": "Drug",
              "start_idx": 257,
              "end_idx": 262
            },
            {
              "entity_id": "T153",
              "entity": "急性胰腺炎",
              "entity_type": "Disease",
              "start_idx": 268,
              "end_idx": 273
            },
            {
              "entity_id": "T154",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 268,
              "end_idx": 270
            },
            {
              "entity_id": "T155",
              "entity": "胰腺",
              "entity_type": "Anatomy",
              "start_idx": 270,
              "end_idx": 272
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R47",
              "head_entity_id": "T121",
              "tail_entity_id": "T120"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R48",
              "head_entity_id": "T123",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R49",
              "head_entity_id": "T124",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R50",
              "head_entity_id": "T125",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R51",
              "head_entity_id": "T130",
              "tail_entity_id": "T129"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R52",
              "head_entity_id": "T133",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R53",
              "head_entity_id": "T135",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R54",
              "head_entity_id": "T137",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R55",
              "head_entity_id": "T139",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R56",
              "head_entity_id": "T135",
              "tail_entity_id": "T134"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R57",
              "head_entity_id": "T137",
              "tail_entity_id": "T134"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R58",
              "head_entity_id": "T139",
              "tail_entity_id": "T134"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R59",
              "head_entity_id": "T148",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R60",
              "head_entity_id": "T150",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R61",
              "head_entity_id": "T151",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R62",
              "head_entity_id": "T152",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R63",
              "head_entity_id": "T155",
              "tail_entity_id": "T153"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R64",
              "head_entity_id": "T154",
              "tail_entity_id": "T153"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "13",
      "paragraph": "(四)抗血小板治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(四)抗血小板治疗",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "14",
      "paragraph": "T2DM患者的高凝血状态是发生心血管事件的重要原因之一。在ASCVD或伴有心血管高危因素的患者中，阿司匹林可有效预防卒中、心肌梗死等心脑血管事件。对于T2DM合并ASCVD患者应常规使用阿司匹林作为二级预防措施，最佳剂量为75~150mg/d；对于阿司匹林过敏或不耐受的患者，可考虑使用氯吡格雷(75mg/d)作为替代治疗。对于急性冠状动脉综合征(ACS)患者，可使用阿司匹林和氯吡格雷双联抗血小板治疗1年。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "T2DM患者的高凝血状态是发生心血管事件的重要原因之一。在ASCVD或伴有心血管高危因素的患者中，阿司匹林可有效预防卒中、心肌梗死等心脑血管事件。对于T2DM合并ASCVD患者应常规使用阿司匹林作为二级预防措施，最佳剂量为75~150mg/d；对于阿司匹林过敏或不耐受的患者，可考虑使用氯吡格雷(75mg/d)作为替代治疗。对于急性冠状动脉综合征(ACS)患者，可使用阿司匹林和氯吡格雷双联抗血小板治疗1年。",
          "start_idx": 0,
          "end_idx": 204,
          "entities": [
            {
              "entity_id": "T156",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T157",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2
            },
            {
              "entity_id": "T158",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 20
            },
            {
              "entity_id": "T159",
              "entity": "高凝血状态",
              "entity_type": "Reason",
              "start_idx": 7,
              "end_idx": 12
            },
            {
              "entity_id": "T160",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 15,
              "end_idx": 18
            },
            {
              "entity_id": "T161",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34
            },
            {
              "entity_id": "T162",
              "entity": "阿司匹林",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53
            },
            {
              "entity_id": "T163",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 60
            },
            {
              "entity_id": "T164",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 65
            },
            {
              "entity_id": "T165",
              "entity": "心脑血管事件",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 72
            },
            {
              "entity_id": "T166",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 61,
              "end_idx": 63
            },
            {
              "entity_id": "T167",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 66,
              "end_idx": 70
            },
            {
              "entity_id": "T168",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 79
            },
            {
              "entity_id": "T169",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 75,
              "end_idx": 77
            },
            {
              "entity_id": "T170",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 86
            },
            {
              "entity_id": "T171",
              "entity": "阿司匹林",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 97
            },
            {
              "entity_id": "T172",
              "entity": "75~150mg/d",
              "entity_type": "Amount",
              "start_idx": 111,
              "end_idx": 121
            },
            {
              "entity_id": "T173",
              "entity": "阿司匹林",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 128
            },
            {
              "entity_id": "T174",
              "entity": "过敏",
              "entity_type": "ADE",
              "start_idx": 128,
              "end_idx": 130
            },
            {
              "entity_id": "T175",
              "entity": "不耐受",
              "entity_type": "ADE",
              "start_idx": 131,
              "end_idx": 134
            },
            {
              "entity_id": "T176",
              "entity": "氯吡格雷",
              "entity_type": "Drug",
              "start_idx": 143,
              "end_idx": 147
            },
            {
              "entity_id": "T177",
              "entity": "75mg/d",
              "entity_type": "Amount",
              "start_idx": 148,
              "end_idx": 154
            },
            {
              "entity_id": "T178",
              "entity": "急性冠状动脉综合征(ACS)",
              "entity_type": "Disease",
              "start_idx": 164,
              "end_idx": 178
            },
            {
              "entity_id": "T179",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 164,
              "end_idx": 166
            },
            {
              "entity_id": "T180",
              "entity": "冠状动脉",
              "entity_type": "Anatomy",
              "start_idx": 166,
              "end_idx": 170
            },
            {
              "entity_id": "T181",
              "entity": "阿司匹林",
              "entity_type": "Drug",
              "start_idx": 184,
              "end_idx": 188
            },
            {
              "entity_id": "T182",
              "entity": "氯吡格雷",
              "entity_type": "Drug",
              "start_idx": 189,
              "end_idx": 193
            },
            {
              "entity_id": "T183",
              "entity": "1年",
              "entity_type": "Duration",
              "start_idx": 201,
              "end_idx": 203
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R65",
              "head_entity_id": "T157",
              "tail_entity_id": "T156"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R66",
              "head_entity_id": "T159",
              "tail_entity_id": "T158"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R67",
              "head_entity_id": "T160",
              "tail_entity_id": "T158"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R68",
              "head_entity_id": "T162",
              "tail_entity_id": "T163"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R69",
              "head_entity_id": "T162",
              "tail_entity_id": "T164"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R70",
              "head_entity_id": "T162",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R71",
              "head_entity_id": "T166",
              "tail_entity_id": "T164"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R72",
              "head_entity_id": "T167",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R73",
              "head_entity_id": "T169",
              "tail_entity_id": "T168"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R74",
              "head_entity_id": "T171",
              "tail_entity_id": "T168"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R75",
              "head_entity_id": "T171",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R76",
              "head_entity_id": "T172",
              "tail_entity_id": "T171"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R77",
              "head_entity_id": "T174",
              "tail_entity_id": "T173"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R78",
              "head_entity_id": "T175",
              "tail_entity_id": "T173"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R79",
              "head_entity_id": "T177",
              "tail_entity_id": "T176"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R80",
              "head_entity_id": "T180",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R81",
              "head_entity_id": "T179",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R82",
              "head_entity_id": "T181",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R83",
              "head_entity_id": "T182",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R84",
              "head_entity_id": "T183",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R85",
              "head_entity_id": "T183",
              "tail_entity_id": "T182"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "15",
      "paragraph": "(五)体重管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(五)体重管理",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [
            {
              "entity_id": "T184",
              "entity": "体重管理",
              "entity_type": "Treatment",
              "start_idx": 3,
              "end_idx": 7
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "16",
      "paragraph": "超重或肥胖、腹型肥胖可增加胰岛素抵抗(IR)，使ASCVD发生风险显著增加。体重控制目标包括体重指数(BMI)<24kg/m2和腰围(WC)达标(男<90cm，女<85cm)。不同降糖药对体重和内脏脂肪的影响存在差异，胰岛素、磺脲类药物(SUs)及噻唑烷二酮类(TZDs)可导致体重增加；二甲双胍可减轻体重，对内脏脂肪的影响尚不明确；胰升糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂既可减轻体重，又可减少内脏脂肪。因此，对于合并超重或肥胖(尤其是腹型肥胖)的T2DM患者，应优先考虑使用兼具减轻体重和减少内脏脂防的降糖药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "超重或肥胖、腹型肥胖可增加胰岛素抵抗(IR)，使ASCVD发生风险显著增加。体重控制目标包括体重指数(BMI)<24kg/m2和腰围(WC)达标(男<90cm，女<85cm)。不同降糖药对体重和内脏脂肪的影响存在差异，胰岛素、磺脲类药物(SUs)及噻唑烷二酮类(TZDs)可导致体重增加；二甲双胍可减轻体重，对内脏脂肪的影响尚不明确；胰升糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂既可减轻体重，又可减少内脏脂肪。因此，对于合并超重或肥胖(尤其是腹型肥胖)的T2DM患者，应优先考虑使用兼具减轻体重和减少内脏脂防的降糖药物。",
          "start_idx": 0,
          "end_idx": 281,
          "entities": [
            {
              "entity_id": "T185",
              "entity": "腹型肥胖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10
            },
            {
              "entity_id": "T186",
              "entity": "超重",
              "entity_type": "Reason",
              "start_idx": 0,
              "end_idx": 2
            },
            {
              "entity_id": "T187",
              "entity": "肥胖",
              "entity_type": "Reason",
              "start_idx": 3,
              "end_idx": 5
            },
            {
              "entity_id": "T188",
              "entity": "胰岛素抵抗(IR)",
              "entity_type": "Pathogenesis",
              "start_idx": 13,
              "end_idx": 22
            },
            {
              "entity_id": "T189",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29
            },
            {
              "entity_id": "T190",
              "entity": "腰围(WC)",
              "entity_type": "Test",
              "start_idx": 64,
              "end_idx": 70
            },
            {
              "entity_id": "T191",
              "entity": "达标(男<90cm，女<85cm)",
              "entity_type": "Test_Value",
              "start_idx": 70,
              "end_idx": 87
            },
            {
              "entity_id": "T192",
              "entity": "体重控制",
              "entity_type": "Treatment",
              "start_idx": 38,
              "end_idx": 42
            },
            {
              "entity_id": "T193",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 112
            },
            {
              "entity_id": "T194",
              "entity": "磺脲类药物(SUs)",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 123
            },
            {
              "entity_id": "T195",
              "entity": "噻唑烷二酮类(TZDs)",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 136
            },
            {
              "entity_id": "T196",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 139,
              "end_idx": 143
            },
            {
              "entity_id": "T197",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 144,
              "end_idx": 148
            },
            {
              "entity_id": "T198",
              "entity": "胰升糖素样肽1(GLP-1)受体激动剂",
              "entity_type": "Drug",
              "start_idx": 167,
              "end_idx": 186
            },
            {
              "entity_id": "T199",
              "entity": "钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 187,
              "end_idx": 210
            },
            {
              "entity_id": "T200",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 233,
              "end_idx": 235
            },
            {
              "entity_id": "T201",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 236,
              "end_idx": 238
            },
            {
              "entity_id": "T202",
              "entity": "腹型肥胖",
              "entity_type": "Disease",
              "start_idx": 242,
              "end_idx": 246
            },
            {
              "entity_id": "T203",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 248,
              "end_idx": 252
            },
            {
              "entity_id": "T204",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 248,
              "end_idx": 250
            },
            {
              "entity_id": "T205",
              "entity": "腹型",
              "entity_type": "Class",
              "start_idx": 242,
              "end_idx": 244
            },
            {
              "entity_id": "T206",
              "entity": "腹型",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R86",
              "head_entity_id": "T206",
              "tail_entity_id": "T185"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R87",
              "head_entity_id": "T186",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R88",
              "head_entity_id": "T187",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R89",
              "head_entity_id": "T188",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R90",
              "head_entity_id": "T196",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R91",
              "head_entity_id": "T196",
              "tail_entity_id": "T194"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R92",
              "head_entity_id": "T196",
              "tail_entity_id": "T195"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R93",
              "head_entity_id": "T205",
              "tail_entity_id": "T202"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R94",
              "head_entity_id": "T204",
              "tail_entity_id": "T203"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "17",
      "paragraph": "(六)血糖管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(六)血糖管理",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [
            {
              "entity_id": "T207",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 3,
              "end_idx": 5
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "18",
      "paragraph": "糖尿病是ASCVD的独立危险因素，不同类型的高血糖状态，包括空腹血糖(FPG)、餐后血糖(PPG)以及HbA1c的升高，均是ASCVD的危险因素。因此，血糖管理是T2DM合并ASCVD患者综合管理策略中的重要组成部分，以下将对此进行详细阐述。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "糖尿病是ASCVD的独立危险因素，不同类型的高血糖状态，包括空腹血糖(FPG)、餐后血糖(PPG)以及HbA1c的升高，均是ASCVD的危险因素。因此，血糖管理是T2DM合并ASCVD患者综合管理策略中的重要组成部分，以下将对此进行详细阐述。",
          "start_idx": 0,
          "end_idx": 121,
          "entities": [
            {
              "entity_id": "T208",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3
            },
            {
              "entity_id": "T209",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T210",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 25
            },
            {
              "entity_id": "T211",
              "entity": "空腹血糖(FPG)",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 39
            },
            {
              "entity_id": "T212",
              "entity": "餐后血糖(PPG)",
              "entity_type": "Test_items",
              "start_idx": 40,
              "end_idx": 49
            },
            {
              "entity_id": "T213",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 56
            },
            {
              "entity_id": "T214",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 57,
              "end_idx": 59
            },
            {
              "entity_id": "T215",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 67
            },
            {
              "entity_id": "T216",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 76,
              "end_idx": 78
            },
            {
              "entity_id": "T217",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 85
            },
            {
              "entity_id": "T218",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 81,
              "end_idx": 83
            },
            {
              "entity_id": "T219",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 87,
              "end_idx": 92
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R95",
              "head_entity_id": "T211",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R96",
              "head_entity_id": "T212",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R97",
              "head_entity_id": "T213",
              "tail_entity_id": "T210"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R98",
              "head_entity_id": "T216",
              "tail_entity_id": "T217"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R99",
              "head_entity_id": "T216",
              "tail_entity_id": "T219"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R100",
              "head_entity_id": "T218",
              "tail_entity_id": "T217"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "19",
      "paragraph": "三、T2DM合并ASCVD患者的血糖管理策略和控制目标",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "三、T2DM合并ASCVD患者的血糖管理策略和控制目标",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T220",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T221",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4
            },
            {
              "entity_id": "T222",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13
            },
            {
              "entity_id": "T223",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 18
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R101",
              "head_entity_id": "T221",
              "tail_entity_id": "T220"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R102",
              "head_entity_id": "T223",
              "tail_entity_id": "T220"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R103",
              "head_entity_id": "T223",
              "tail_entity_id": "T222"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "20",
      "paragraph": "对于T2DM合并ASCVD患者，血糖管理的总原则是必须兼顾降糖有效性和心血管安全性，并且优先考虑选择具有心血管获益证据的降糖药物。英国糖尿病前瞻性研究(UKPDS)及其后续的10年随访研究显示，在新诊断的T2DM患者中，严格血糖控制(HbA1c<7.0%)对降低心血管事件的远期风险非常重要。然而，退伍军人糖尿病研究(VADT)、控制糖尿病患者心血管风险行动研究(ACCORD)、糖尿病与血管疾病行动研究(AD-VANCE)等随机对照临床试验(RCTs)均显示，在年龄较大、病程较长或合并ASCVD的T2DM患者中，强化降糖治疗并不能显著降低心血管事件风险。此外，对于合并ASCVD的T2DM患者，一旦发生低血糖还可能诱发心律失常、心肌梗死、卒中、猝死等。因此，对于这类患者而言，降糖治疗的安全性可能比降糖疗效更为重要，应尽量在避免低血糖的前提下使血糖控制达标。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于T2DM合并ASCVD患者，血糖管理的总原则是必须兼顾降糖有效性和心血管安全性，并且优先考虑选择具有心血管获益证据的降糖药物。英国糖尿病前瞻性研究(UKPDS)及其后续的10年随访研究显示，在新诊断的T2DM患者中，严格血糖控制(HbA1c<7.0%)对降低心血管事件的远期风险非常重要。然而，退伍军人糖尿病研究(VADT)、控制糖尿病患者心血管风险行动研究(ACCORD)、糖尿病与血管疾病行动研究(AD-VANCE)等随机对照临床试验(RCTs)均显示，在年龄较大、病程较长或合并ASCVD的T2DM患者中，强化降糖治疗并不能显著降低心血管事件风险。此外，对于合并ASCVD的T2DM患者，一旦发生低血糖还可能诱发心律失常、心肌梗死、卒中、猝死等。",
          "start_idx": 0,
          "end_idx": 328,
          "entities": [
            {
              "entity_id": "T224",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T225",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4
            },
            {
              "entity_id": "T226",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13
            },
            {
              "entity_id": "T227",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 18
            },
            {
              "entity_id": "T228",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 67,
              "end_idx": 70
            },
            {
              "entity_id": "T229",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 102,
              "end_idx": 106
            },
            {
              "entity_id": "T230",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 102,
              "end_idx": 104
            },
            {
              "entity_id": "T231",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 112,
              "end_idx": 114
            },
            {
              "entity_id": "T232",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 117,
              "end_idx": 122
            },
            {
              "entity_id": "T233",
              "entity": "<7.0%",
              "entity_type": "Test_Value",
              "start_idx": 122,
              "end_idx": 127
            },
            {
              "entity_id": "T234",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 131,
              "end_idx": 136
            },
            {
              "entity_id": "T235",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 131,
              "end_idx": 134
            },
            {
              "entity_id": "T236",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 153,
              "end_idx": 156
            },
            {
              "entity_id": "T237",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 167,
              "end_idx": 170
            },
            {
              "entity_id": "T238",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 190,
              "end_idx": 193
            },
            {
              "entity_id": "T239",
              "entity": "血管疾病",
              "entity_type": "Disease",
              "start_idx": 194,
              "end_idx": 198
            },
            {
              "entity_id": "T240",
              "entity": "血管",
              "entity_type": "Anatomy",
              "start_idx": 194,
              "end_idx": 196
            },
            {
              "entity_id": "T241",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 244,
              "end_idx": 249
            },
            {
              "entity_id": "T242",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 250,
              "end_idx": 254
            },
            {
              "entity_id": "T243",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 250,
              "end_idx": 252
            },
            {
              "entity_id": "T244",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 271,
              "end_idx": 276
            },
            {
              "entity_id": "T245",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 271,
              "end_idx": 274
            },
            {
              "entity_id": "T246",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 286,
              "end_idx": 291
            },
            {
              "entity_id": "T247",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 292,
              "end_idx": 296
            },
            {
              "entity_id": "T248",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 292,
              "end_idx": 294
            },
            {
              "entity_id": "T249",
              "entity": "低血糖",
              "entity_type": "Reason",
              "start_idx": 303,
              "end_idx": 306
            },
            {
              "entity_id": "T250",
              "entity": "心律失常",
              "entity_type": "Disease",
              "start_idx": 311,
              "end_idx": 315
            },
            {
              "entity_id": "T251",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 316,
              "end_idx": 320
            },
            {
              "entity_id": "T252",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 316,
              "end_idx": 318
            },
            {
              "entity_id": "T253",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 321,
              "end_idx": 323
            },
            {
              "entity_id": "T254",
              "entity": "猝死",
              "entity_type": "Disease",
              "start_idx": 324,
              "end_idx": 326
            },
            {
              "entity_id": "T257",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 172,
              "end_idx": 175
            },
            {
              "entity_id": "T258",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 311,
              "end_idx": 312
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R104",
              "head_entity_id": "T225",
              "tail_entity_id": "T224"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R105",
              "head_entity_id": "T227",
              "tail_entity_id": "T224"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R106",
              "head_entity_id": "T227",
              "tail_entity_id": "T226"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R107",
              "head_entity_id": "T230",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R108",
              "head_entity_id": "T231",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R109",
              "head_entity_id": "T232",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R110",
              "head_entity_id": "T235",
              "tail_entity_id": "T234"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R111",
              "head_entity_id": "T257",
              "tail_entity_id": "T237"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R112",
              "head_entity_id": "T240",
              "tail_entity_id": "T239"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R113",
              "head_entity_id": "T243",
              "tail_entity_id": "T242"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R114",
              "head_entity_id": "T245",
              "tail_entity_id": "T244"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R115",
              "head_entity_id": "T248",
              "tail_entity_id": "T247"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R116",
              "head_entity_id": "T249",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R117",
              "head_entity_id": "T249",
              "tail_entity_id": "T251"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R118",
              "head_entity_id": "T249",
              "tail_entity_id": "T253"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R119",
              "head_entity_id": "T249",
              "tail_entity_id": "T254"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R120",
              "head_entity_id": "T258",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R121",
              "head_entity_id": "T252",
              "tail_entity_id": "T251"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "因此，对于这类患者而言，降糖治疗的安全性可能比降糖疗效更为重要，应尽量在避免低血糖的前提下使血糖控制达标。",
          "start_idx": 328,
          "end_idx": 381,
          "entities": [
            {
              "entity_id": "T255",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 46,
              "end_idx": 48
            },
            {
              "entity_id": "T256",
              "entity": "控制达标",
              "entity_type": "Test_Value",
              "start_idx": 48,
              "end_idx": 52
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "21",
      "paragraph": "本共识建议，T2DM合并ASCVD患者的血糖控制目标应该遵循个体化原则-综合考虑患者的年龄、糖尿病病程、ASCVD病史、其他并发症或合并症、低血糖风险等因素，充分平衡严格血糖控制的利弊得失。基于现有的循证医学证据，本共识推荐T2DM合并ASCVD患者的血控制目标如下：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "本共识建议，T2DM合并ASCVD患者的血糖控制目标应该遵循个体化原则-综合考虑患者的年龄、糖尿病病程、ASCVD病史、其他并发症或合并症、低血糖风险等因素，充分平衡严格血糖控制的利弊得失。",
          "start_idx": 0,
          "end_idx": 95,
          "entities": [
            {
              "entity_id": "T259",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10
            },
            {
              "entity_id": "T260",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8
            },
            {
              "entity_id": "T261",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 17
            },
            {
              "entity_id": "T262",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 20,
              "end_idx": 22
            },
            {
              "entity_id": "T263",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 49
            },
            {
              "entity_id": "T264",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 57
            },
            {
              "entity_id": "T265",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 70,
              "end_idx": 73
            },
            {
              "entity_id": "T266",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 85,
              "end_idx": 87
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R122",
              "head_entity_id": "T260",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R123",
              "head_entity_id": "T262",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R124",
              "head_entity_id": "T262",
              "tail_entity_id": "T261"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "基于现有的循证医学证据，本共识推荐T2DM合并ASCVD患者的血控制目标如下：",
          "start_idx": 95,
          "end_idx": 134,
          "entities": [
            {
              "entity_id": "T267",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 21
            },
            {
              "entity_id": "T268",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 28
            },
            {
              "entity_id": "T269",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 17,
              "end_idx": 19
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R125",
              "head_entity_id": "T269",
              "tail_entity_id": "T267"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "22",
      "paragraph": "1.对于大多数患者，HbA1c目标应控制在<7.0%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.对于大多数患者，HbA1c目标应控制在<7.0%。",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T270",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 10,
              "end_idx": 15
            },
            {
              "entity_id": "T271",
              "entity": "<7.0%",
              "entity_type": "Test_Value",
              "start_idx": 21,
              "end_idx": 26
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "23",
      "paragraph": "2.对于年龄较大、糖尿病病程较长、存在低血糖高危因素的患者，HbA1c目标应控制在<7.5%或<8.0%.",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.对于年龄较大、糖尿病病程较长、存在低血糖高危因素的患者，HbA1c目标应控制在<7.5%或<8.0%.",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T272",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12
            },
            {
              "entity_id": "T273",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 22
            },
            {
              "entity_id": "T274",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 35
            },
            {
              "entity_id": "T275",
              "entity": "<7.5%或<8.0%",
              "entity_type": "Test_Value",
              "start_idx": 41,
              "end_idx": 52
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R126",
              "head_entity_id": "T274",
              "tail_entity_id": "T272"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R127",
              "head_entity_id": "T274",
              "tail_entity_id": "T273"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "24",
      "paragraph": "3.对于慢性疾病终末期患者，如纽约心脏学会(NYHA)心功能Ⅲ-IV级、终末期肾病、恶性肿瘤伴有转移、中重度认知功能障碍等，HbA1c控制目标可适当放宽至<8.5%。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.对于慢性疾病终末期患者，如纽约心脏学会(NYHA)心功能Ⅲ-IV级、终末期肾病、恶性肿瘤伴有转移、中重度认知功能障碍等，HbA1c控制目标可适当放宽至<8.5%。",
          "start_idx": 0,
          "end_idx": 83,
          "entities": [
            {
              "entity_id": "T276",
              "entity": "心功能Ⅲ-IV级",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 35
            },
            {
              "entity_id": "T277",
              "entity": "Ⅲ-IV级",
              "entity_type": "Class",
              "start_idx": 30,
              "end_idx": 35
            },
            {
              "entity_id": "T278",
              "entity": "终末期肾病",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 41
            },
            {
              "entity_id": "T279",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 36,
              "end_idx": 39
            },
            {
              "entity_id": "T280",
              "entity": "恶性肿瘤伴有转移",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 50
            },
            {
              "entity_id": "T281",
              "entity": "中重度认知功能障碍",
              "entity_type": "Disease",
              "start_idx": 51,
              "end_idx": 60
            },
            {
              "entity_id": "T282",
              "entity": "中重度",
              "entity_type": "Class",
              "start_idx": 51,
              "end_idx": 54
            },
            {
              "entity_id": "T283",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 67
            },
            {
              "entity_id": "T284",
              "entity": "<8.5%",
              "entity_type": "Test_Value",
              "start_idx": 77,
              "end_idx": 82
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R128",
              "head_entity_id": "T283",
              "tail_entity_id": "T276"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R129",
              "head_entity_id": "T277",
              "tail_entity_id": "T276"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R130",
              "head_entity_id": "T283",
              "tail_entity_id": "T278"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R131",
              "head_entity_id": "T279",
              "tail_entity_id": "T278"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R132",
              "head_entity_id": "T283",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R133",
              "head_entity_id": "T283",
              "tail_entity_id": "T281"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R134",
              "head_entity_id": "T282",
              "tail_entity_id": "T281"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "25",
      "paragraph": "四、T2DM合并ASCVD患者的降糖药物治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "四、T2DM合并ASCVD患者的降糖药物治疗",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T285",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T286",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4
            },
            {
              "entity_id": "T287",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R135",
              "head_entity_id": "T286",
              "tail_entity_id": "T285"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "26",
      "paragraph": "(一)降糖药物的心血管安全性评价",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(一)降糖药物的心血管安全性评价",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "27",
      "paragraph": "2008年，美国食品药品监督管理局(FDA)发布了强制性指导意见，要求所有新批准上市的降糖药都必须进行心血管安全性评估。根据这一要求.目前全球已开展了一系列新型降糖药物的心血管结局研究(CVOT)。传统降糖药物由于不受这条强制性要求的制约，故缺少CVOT证据，其心血管安全性评估通常基于针对降糖治疗策略的大型RCT数据或基于针对降糖疗效的多项RCTs荟萃分析结果。根据目前已有的CVOT证据(表1)，本共识将降糖药物的心血管安全性分为获益、中性及其他3大类。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2008年，美国食品药品监督管理局(FDA)发布了强制性指导意见，要求所有新批准上市的降糖药都必须进行心血管安全性评估。",
          "start_idx": 0,
          "end_idx": 60,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "根据这一要求.目前全球已开展了一系列新型降糖药物的心血管结局研究(CVOT)。",
          "start_idx": 60,
          "end_idx": 99,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "传统降糖药物由于不受这条强制性要求的制约，故缺少CVOT证据，其心血管安全性评估通常基于针对降糖治疗策略的大型RCT数据或基于针对降糖疗效的多项RCTs荟萃分析结果。",
          "start_idx": 99,
          "end_idx": 182,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "根据目前已有的CVOT证据(表1)，本共识将降糖药物的心血管安全性分为获益、中性及其他3大类。",
          "start_idx": 182,
          "end_idx": 229,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "28",
      "paragraph": "1.具有心血管获益证据的降糖药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.具有心血管获益证据的降糖药物",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "29",
      "paragraph": "目前，明确具有心血管获益的降糖药物包括二甲双胍、恩格列净及利拉鲁肽。二甲双胍是T2DM降糖治疗的一线药物，其心血管安全性证据来自UKPDS及其后续的10年随访研究。UKPDS研究纳人1704例合并超重或肥胖的新诊断T2DM患者，随机分为给予传统治疗(饮食控制为主，n=411)、二甲双胍强化降糖治疗(n=342)或其他药物(SUs或胰岛素)强化降糖治疗(n=951)，中位随访时间为10.7年。结果显示，与传统治疗相比，二甲双胍可显著降低心血管事件风险，其中心肌梗死风险下降39%(P=0.010)，心血管事件复合终点(心肌梗死、猝死、心绞痛、卒中或周围血管疾病)风险下降30%(P=0.020)；二甲双胍与其他药物的两种强化降糖治疗方案之间相比，心血管事件风险差异无统计学意义。UKPDS研究结束后继续随访10年仍发现，二甲双胍的心血管获益具有延续效应，与传统治疗相比，其心肌梗死风险下降33%(P=0.005)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前，明确具有心血管获益的降糖药物包括二甲双胍、恩格列净及利拉鲁肽。二甲双胍是T2DM降糖治疗的一线药物，其心血管安全性证据来自UKPDS及其后续的10年随访研究。UKPDS研究纳人1704例合并超重或肥胖的新诊断T2DM患者，随机分为给予传统治疗(饮食控制为主，n=411)、二甲双胍强化降糖治疗(n=342)或其他药物(SUs或胰岛素)强化降糖治疗(n=951)，中位随访时间为10.7年。结果显示，与传统治疗相比，二甲双胍可显著降低心血管事件风险，其中心肌梗死风险下降39%(P=0.010)，心血管事件复合终点(心肌梗死、猝死、心绞痛、卒中或周围血管疾病)风险下降30%(P=0.020)；二甲双胍与其他药物的两种强化降糖治疗方案之间相比，心血管事件风险差异无统计学意义。UKPDS研究结束后继续随访10年仍发现，二甲双胍的心血管获益具有延续效应，与传统治疗相比，其心肌梗死风险下降33%(P=0.005)。",
          "start_idx": 0,
          "end_idx": 408,
          "entities": [
            {
              "entity_id": "T288",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23
            },
            {
              "entity_id": "T289",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 28
            },
            {
              "entity_id": "T290",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 33
            },
            {
              "entity_id": "T291",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38
            },
            {
              "entity_id": "T292",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 43
            },
            {
              "entity_id": "T293",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 39,
              "end_idx": 41
            },
            {
              "entity_id": "T294",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 98,
              "end_idx": 100
            },
            {
              "entity_id": "T295",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 103
            },
            {
              "entity_id": "T296",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 111
            },
            {
              "entity_id": "T297",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 107,
              "end_idx": 109
            },
            {
              "entity_id": "T298",
              "entity": "饮食控制",
              "entity_type": "Treatment",
              "start_idx": 125,
              "end_idx": 129
            },
            {
              "entity_id": "T299",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 139,
              "end_idx": 143
            },
            {
              "entity_id": "T300",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 162,
              "end_idx": 165
            },
            {
              "entity_id": "T301",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 166,
              "end_idx": 169
            },
            {
              "entity_id": "T302",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 210,
              "end_idx": 214
            },
            {
              "entity_id": "T303",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 219,
              "end_idx": 224
            },
            {
              "entity_id": "T304",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 219,
              "end_idx": 222
            },
            {
              "entity_id": "T305",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 229,
              "end_idx": 233
            },
            {
              "entity_id": "T306",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 229,
              "end_idx": 231
            },
            {
              "entity_id": "T307",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 250,
              "end_idx": 255
            },
            {
              "entity_id": "T308",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 250,
              "end_idx": 253
            },
            {
              "entity_id": "T309",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 260,
              "end_idx": 264
            },
            {
              "entity_id": "T310",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 260,
              "end_idx": 262
            },
            {
              "entity_id": "T311",
              "entity": "猝死",
              "entity_type": "Disease",
              "start_idx": 265,
              "end_idx": 267
            },
            {
              "entity_id": "T312",
              "entity": "心绞痛",
              "entity_type": "Disease",
              "start_idx": 268,
              "end_idx": 271
            },
            {
              "entity_id": "T313",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 268,
              "end_idx": 269
            },
            {
              "entity_id": "T314",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 272,
              "end_idx": 274
            },
            {
              "entity_id": "T315",
              "entity": "周围血管疾病",
              "entity_type": "Disease",
              "start_idx": 275,
              "end_idx": 281
            },
            {
              "entity_id": "T316",
              "entity": "周围血管",
              "entity_type": "Anatomy",
              "start_idx": 275,
              "end_idx": 279
            },
            {
              "entity_id": "T317",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 299,
              "end_idx": 303
            },
            {
              "entity_id": "T318",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 324,
              "end_idx": 329
            },
            {
              "entity_id": "T319",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 324,
              "end_idx": 327
            },
            {
              "entity_id": "T320",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 361,
              "end_idx": 365
            },
            {
              "entity_id": "T321",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 387,
              "end_idx": 391
            },
            {
              "entity_id": "T322",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 387,
              "end_idx": 389
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R136",
              "head_entity_id": "T291",
              "tail_entity_id": "T292"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R137",
              "head_entity_id": "T293",
              "tail_entity_id": "T292"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R138",
              "head_entity_id": "T297",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R139",
              "head_entity_id": "T298",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R140",
              "head_entity_id": "T299",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R141",
              "head_entity_id": "T300",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R142",
              "head_entity_id": "T301",
              "tail_entity_id": "T296"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R143",
              "head_entity_id": "T304",
              "tail_entity_id": "T303"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R144",
              "head_entity_id": "T306",
              "tail_entity_id": "T305"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R145",
              "head_entity_id": "T308",
              "tail_entity_id": "T307"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R146",
              "head_entity_id": "T310",
              "tail_entity_id": "T309"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R147",
              "head_entity_id": "T313",
              "tail_entity_id": "T312"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R148",
              "head_entity_id": "T316",
              "tail_entity_id": "T315"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R149",
              "head_entity_id": "T319",
              "tail_entity_id": "T318"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R150",
              "head_entity_id": "T322",
              "tail_entity_id": "T321"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "30",
      "paragraph": "SGLT-2抑制剂恩格列净是第一个通过CVOT证实具有明确心血管获益的新型降糖药物，但目前尚未在我国上市。恩格列净心血管事件结局(EM-PA-REG OUTCOME)研究纳入7020例伴有心血管疾病的T2DM患者，中位随访时间为3.1年。结果显示，在常规治疗基础上，与安慰剂相比，恩格列净可显著降低3终点的主要心血管不良事件(3终点MACE，包括心血管死亡、非致死性心肌梗死或非致死性卒中)风险14%(P=0.04)，降低心血管死亡风险38%(P<0.001)，降低心力衰竭住院风险35%(P=0.002)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂恩格列净是第一个通过CVOT证实具有明确心血管获益的新型降糖药物，但目前尚未在我国上市。恩格列净心血管事件结局(EM-PA-REG OUTCOME)研究纳入7020例伴有心血管疾病的T2DM患者，中位随访时间为3.1年。结果显示，在常规治疗基础上，与安慰剂相比，恩格列净可显著降低3终点的主要心血管不良事件(3终点MACE，包括心血管死亡、非致死性心肌梗死或非致死性卒中)风险14%(P=0.04)，降低心血管死亡风险38%(P<0.001)，降低心力衰竭住院风险35%(P=0.002)。",
          "start_idx": 0,
          "end_idx": 254,
          "entities": [
            {
              "entity_id": "T323",
              "entity": "SGLT-2抑制剂恩格列净",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 13
            },
            {
              "entity_id": "T324",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T325",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 62
            },
            {
              "entity_id": "T326",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 57,
              "end_idx": 60
            },
            {
              "entity_id": "T327",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 94,
              "end_idx": 99
            },
            {
              "entity_id": "T328",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 94,
              "end_idx": 97
            },
            {
              "entity_id": "T329",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 100,
              "end_idx": 104
            },
            {
              "entity_id": "T330",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 100,
              "end_idx": 102
            },
            {
              "entity_id": "T331",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 140,
              "end_idx": 144
            },
            {
              "entity_id": "T332",
              "entity": "非致死性心肌梗死",
              "entity_type": "Disease",
              "start_idx": 179,
              "end_idx": 187
            },
            {
              "entity_id": "T333",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 183,
              "end_idx": 185
            },
            {
              "entity_id": "T334",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 179,
              "end_idx": 183
            },
            {
              "entity_id": "T335",
              "entity": "非致死性卒中",
              "entity_type": "Disease",
              "start_idx": 188,
              "end_idx": 194
            },
            {
              "entity_id": "T336",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 188,
              "end_idx": 192
            },
            {
              "entity_id": "T337",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 233,
              "end_idx": 237
            },
            {
              "entity_id": "T338",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 233,
              "end_idx": 234
            },
            {
              "entity_id": "T339",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 173,
              "end_idx": 178
            },
            {
              "entity_id": "T340",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 173,
              "end_idx": 176
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R151",
              "head_entity_id": "T326",
              "tail_entity_id": "T325"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R152",
              "head_entity_id": "T328",
              "tail_entity_id": "T327"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R153",
              "head_entity_id": "T330",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R154",
              "head_entity_id": "T333",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R155",
              "head_entity_id": "T334",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R156",
              "head_entity_id": "T336",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R157",
              "head_entity_id": "T338",
              "tail_entity_id": "T337"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R158",
              "head_entity_id": "T340",
              "tail_entity_id": "T339"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "31",
      "paragraph": "GLP-1受体激动剂利拉鲁肽是目前在中国上市的降糖药物中唯一被CVOT证实具有心血管获益的降糖药物。利拉鲁肽在糖尿病患者中的心血管结局评估(LEADER)研究纳入9340例伴有心血管疾或心血管危险因素的T2DM患者，其中81.3%的患者既往有心血管病史(包括心肌梗死、卒中或短暂性脑缺血发作、曾行血运重建术、冠状动脉或颈动脉或下肢动脉狭窄≥50%)，中位随访时间为3.8年。结果显示，在常规治疗基础上，与安慰剂相比利拉鲁肽可使3终点MACE风险降低13%(P<0.001)-心血管死亡风险降低22%(P=0.007)，扩展的心血管事件复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中、血运重建、不稳定性心绞痛住院或心力衰竭住院)风险降低12%(P=0.005)，且不增加心力衰竭住院风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "GLP-1受体激动剂利拉鲁肽是目前在中国上市的降糖药物中唯一被CVOT证实具有心血管获益的降糖药物。利拉鲁肽在糖尿病患者中的心血管结局评估(LEADER)研究纳入9340例伴有心血管疾或心血管危险因素的T2DM患者，其中81.3%的患者既往有心血管病史(包括心肌梗死、卒中或短暂性脑缺血发作、曾行血运重建术、冠状动脉或颈动脉或下肢动脉狭窄≥50%)，中位随访时间为3.8年。结果显示，在常规治疗基础上，与安慰剂相比利拉鲁肽可使3终点MACE风险降低13%(P<0.001)-心血管死亡风险降低22%(P=0.007)，扩展的心血管事件复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中、血运重建、不稳定性心绞痛住院或心力衰竭住院)风险降低12%(P=0.005)，且不增加心力衰竭住院风险。",
          "start_idx": 0,
          "end_idx": 346,
          "entities": [
            {
              "entity_id": "T341",
              "entity": "GLP-1受体激动剂利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 14
            },
            {
              "entity_id": "T342",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 54
            },
            {
              "entity_id": "T343",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 55,
              "end_idx": 58
            },
            {
              "entity_id": "T344",
              "entity": "心血管疾",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 92
            },
            {
              "entity_id": "T345",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 88,
              "end_idx": 91
            },
            {
              "entity_id": "T346",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 105
            },
            {
              "entity_id": "T347",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 101,
              "end_idx": 103
            },
            {
              "entity_id": "T348",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 129,
              "end_idx": 133
            },
            {
              "entity_id": "T349",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 129,
              "end_idx": 131
            },
            {
              "entity_id": "T350",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 134,
              "end_idx": 136
            },
            {
              "entity_id": "T351",
              "entity": "短暂性脑缺血发作",
              "entity_type": "Disease",
              "start_idx": 137,
              "end_idx": 145
            },
            {
              "entity_id": "T352",
              "entity": "脑",
              "entity_type": "Anatomy",
              "start_idx": 140,
              "end_idx": 141
            },
            {
              "entity_id": "T353",
              "entity": "短暂性",
              "entity_type": "Class",
              "start_idx": 137,
              "end_idx": 140
            },
            {
              "entity_id": "T354",
              "entity": "血运重建术",
              "entity_type": "Operation",
              "start_idx": 148,
              "end_idx": 153
            },
            {
              "entity_id": "T355",
              "entity": "冠状动脉或颈动脉或下肢动脉狭窄",
              "entity_type": "Disease",
              "start_idx": 154,
              "end_idx": 169
            },
            {
              "entity_id": "T356",
              "entity": "冠状动脉",
              "entity_type": "Anatomy",
              "start_idx": 154,
              "end_idx": 158
            },
            {
              "entity_id": "T357",
              "entity": "颈动脉",
              "entity_type": "Anatomy",
              "start_idx": 159,
              "end_idx": 162
            },
            {
              "entity_id": "T358",
              "entity": "下肢动脉",
              "entity_type": "Anatomy",
              "start_idx": 163,
              "end_idx": 167
            },
            {
              "entity_id": "T359",
              "entity": "≥50%",
              "entity_type": "Level",
              "start_idx": 169,
              "end_idx": 173
            },
            {
              "entity_id": "T360",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 207,
              "end_idx": 211
            },
            {
              "entity_id": "T361",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 262,
              "end_idx": 267
            },
            {
              "entity_id": "T362",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 262,
              "end_idx": 265
            },
            {
              "entity_id": "T363",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 237,
              "end_idx": 242
            },
            {
              "entity_id": "T364",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 237,
              "end_idx": 240
            },
            {
              "entity_id": "T365",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 272,
              "end_idx": 277
            },
            {
              "entity_id": "T366",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 272,
              "end_idx": 275
            },
            {
              "entity_id": "T367",
              "entity": "非致死性心肌梗死",
              "entity_type": "Disease",
              "start_idx": 278,
              "end_idx": 286
            },
            {
              "entity_id": "T368",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 278,
              "end_idx": 282
            },
            {
              "entity_id": "T369",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 282,
              "end_idx": 284
            },
            {
              "entity_id": "T370",
              "entity": "非致死性卒中",
              "entity_type": "Disease",
              "start_idx": 287,
              "end_idx": 293
            },
            {
              "entity_id": "T371",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 287,
              "end_idx": 291
            },
            {
              "entity_id": "T372",
              "entity": "血运重建",
              "entity_type": "Operation",
              "start_idx": 294,
              "end_idx": 298
            },
            {
              "entity_id": "T373",
              "entity": "不稳定性心绞痛",
              "entity_type": "Disease",
              "start_idx": 299,
              "end_idx": 306
            },
            {
              "entity_id": "T374",
              "entity": "不稳定性",
              "entity_type": "Class",
              "start_idx": 299,
              "end_idx": 303
            },
            {
              "entity_id": "T375",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 303,
              "end_idx": 304
            },
            {
              "entity_id": "T376",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 309,
              "end_idx": 313
            },
            {
              "entity_id": "T377",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 309,
              "end_idx": 310
            },
            {
              "entity_id": "T378",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 337,
              "end_idx": 341
            },
            {
              "entity_id": "T379",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 337,
              "end_idx": 338
            },
            {
              "entity_id": "T380",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 62,
              "end_idx": 65
            },
            {
              "entity_id": "T381",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 93,
              "end_idx": 96
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R159",
              "head_entity_id": "T342",
              "tail_entity_id": "T343"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R160",
              "head_entity_id": "T380",
              "tail_entity_id": "T343"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R161",
              "head_entity_id": "T345",
              "tail_entity_id": "T344"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R162",
              "head_entity_id": "T347",
              "tail_entity_id": "T346"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R163",
              "head_entity_id": "T381",
              "tail_entity_id": "T346"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R164",
              "head_entity_id": "T349",
              "tail_entity_id": "T348"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R165",
              "head_entity_id": "T352",
              "tail_entity_id": "T351"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R166",
              "head_entity_id": "T353",
              "tail_entity_id": "T351"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R167",
              "head_entity_id": "T356",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R168",
              "head_entity_id": "T357",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R169",
              "head_entity_id": "T358",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R170",
              "head_entity_id": "T362",
              "tail_entity_id": "T361"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R171",
              "head_entity_id": "T364",
              "tail_entity_id": "T363"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R172",
              "head_entity_id": "T366",
              "tail_entity_id": "T365"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R173",
              "head_entity_id": "T369",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R174",
              "head_entity_id": "T368",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R175",
              "head_entity_id": "T371",
              "tail_entity_id": "T370"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R176",
              "head_entity_id": "T374",
              "tail_entity_id": "T373"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R177",
              "head_entity_id": "T375",
              "tail_entity_id": "T373"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R178",
              "head_entity_id": "T377",
              "tail_entity_id": "T376"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R179",
              "head_entity_id": "T379",
              "tail_entity_id": "T378"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "32",
      "paragraph": "EMPA-REG OUTCOME和LEADER均为大型、多中心、随机、双盲、安慰剂对照的CVOT，这两项研究分别为恩格列净和利拉鲁肽的心血管保护作用提供了可靠证据，对于T2DM合并ASCVD患者的降糖治疗策略制定具有里程碑意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "EMPA-REG OUTCOME和LEADER均为大型、多中心、随机、双盲、安慰剂对照的CVOT，这两项研究分别为恩格列净和利拉鲁肽的心血管保护作用提供了可靠证据，对于T2DM合并ASCVD患者的降糖治疗策略制定具有里程碑意义。",
          "start_idx": 0,
          "end_idx": 114,
          "entities": [
            {
              "entity_id": "T382",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61
            },
            {
              "entity_id": "T383",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 62,
              "end_idx": 66
            },
            {
              "entity_id": "T384",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 84,
              "end_idx": 88
            },
            {
              "entity_id": "T385",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 84,
              "end_idx": 86
            },
            {
              "entity_id": "T386",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 90,
              "end_idx": 95
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R180",
              "head_entity_id": "T382",
              "tail_entity_id": "T384"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R181",
              "head_entity_id": "T382",
              "tail_entity_id": "T386"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R182",
              "head_entity_id": "T383",
              "tail_entity_id": "T384"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R183",
              "head_entity_id": "T383",
              "tail_entity_id": "T386"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R184",
              "head_entity_id": "T385",
              "tail_entity_id": "T384"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "33",
      "paragraph": "2.具有心血管效应为中性证据的降糖药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.具有心血管效应为中性证据的降糖药物",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "34",
      "paragraph": "在T2DM患者中CVOT证实心血管效应为中性的降糖药物包括罗格列酮、吡格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "在T2DM患者中CVOT证实心血管效应为中性的降糖药物包括罗格列酮、吡格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽。",
          "start_idx": 0,
          "end_idx": 65,
          "entities": [
            {
              "entity_id": "T387",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 1,
              "end_idx": 5
            },
            {
              "entity_id": "T388",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 1,
              "end_idx": 3
            },
            {
              "entity_id": "T389",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 33
            },
            {
              "entity_id": "T390",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38
            },
            {
              "entity_id": "T391",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 44
            },
            {
              "entity_id": "T392",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 49
            },
            {
              "entity_id": "T393",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 54
            },
            {
              "entity_id": "T394",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 59
            },
            {
              "entity_id": "T395",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 64
            },
            {
              "entity_id": "T396",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 17
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R185",
              "head_entity_id": "T388",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R186",
              "head_entity_id": "T396",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R187",
              "head_entity_id": "T389",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R188",
              "head_entity_id": "T390",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R189",
              "head_entity_id": "T391",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R190",
              "head_entity_id": "T392",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R191",
              "head_entity_id": "T393",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R192",
              "head_entity_id": "T394",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R193",
              "head_entity_id": "T395",
              "tail_entity_id": "T387"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "35",
      "paragraph": "评估罗格列酮对糖尿病患者心血管结局和血糖控制影响(RECORD)研究是一项开放标签的RCT研究，4447例二甲双胍或SUs单药治疗血糖控制不佳的T2DM患者随机分为两组：在原有治疗基础上联合罗格列酮或在原有治疗基础上联合SUs或双胍类，平均随访时间为5.5年。结果显示与二甲双胍联合SUs治疗组相比，罗格列酮联合二甲双胍或SUs组的首要心血管终点事件(心血管疾病住院或心血管死亡)风险达到非劣效性标准(HR为0.99.95%CI为0.85~1.16)；心力衰竭住院或死亡的相对风险显著增加(HR2.10，95%CI 1.35~3.27)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "评估罗格列酮对糖尿病患者心血管结局和血糖控制影响(RECORD)研究是一项开放标签的RCT研究，4447例二甲双胍或SUs单药治疗血糖控制不佳的T2DM患者随机分为两组：在原有治疗基础上联合罗格列酮或在原有治疗基础上联合SUs或双胍类，平均随访时间为5.5年。结果显示与二甲双胍联合SUs治疗组相比，罗格列酮联合二甲双胍或SUs组的首要心血管终点事件(心血管疾病住院或心血管死亡)风险达到非劣效性标准(HR为0.99.95%CI为0.85~1.16)；心力衰竭住院或死亡的相对风险显著增加(HR2.10，95%CI 1.35~3.27)",
          "start_idx": 0,
          "end_idx": 268,
          "entities": [
            {
              "entity_id": "T397",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T398",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10
            },
            {
              "entity_id": "T399",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 20
            },
            {
              "entity_id": "T400",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T401",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 61
            },
            {
              "entity_id": "T402",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 65,
              "end_idx": 67
            },
            {
              "entity_id": "T403",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 76
            },
            {
              "entity_id": "T404",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 72,
              "end_idx": 74
            },
            {
              "entity_id": "T405",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99
            },
            {
              "entity_id": "T406",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 110,
              "end_idx": 113
            },
            {
              "entity_id": "T407",
              "entity": "双胍类",
              "entity_type": "Drug",
              "start_idx": 114,
              "end_idx": 117
            },
            {
              "entity_id": "T408",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 135,
              "end_idx": 139
            },
            {
              "entity_id": "T409",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 144
            },
            {
              "entity_id": "T410",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 154
            },
            {
              "entity_id": "T411",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 156,
              "end_idx": 160
            },
            {
              "entity_id": "T412",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 161,
              "end_idx": 164
            },
            {
              "entity_id": "T413",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 176,
              "end_idx": 181
            },
            {
              "entity_id": "T414",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 184,
              "end_idx": 189
            },
            {
              "entity_id": "T415",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 226,
              "end_idx": 230
            },
            {
              "entity_id": "T416",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 176,
              "end_idx": 179
            },
            {
              "entity_id": "T417",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 226,
              "end_idx": 227
            },
            {
              "entity_id": "T418",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 184,
              "end_idx": 187
            },
            {
              "entity_id": "T419",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 67,
              "end_idx": 71
            },
            {
              "entity_id": "T420",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 15
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R194",
              "head_entity_id": "T397",
              "tail_entity_id": "T398"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R195",
              "head_entity_id": "T420",
              "tail_entity_id": "T398"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R196",
              "head_entity_id": "T399",
              "tail_entity_id": "T398"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R197",
              "head_entity_id": "T400",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R198",
              "head_entity_id": "T401",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R199",
              "head_entity_id": "T402",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R200",
              "head_entity_id": "T404",
              "tail_entity_id": "T403"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R201",
              "head_entity_id": "T416",
              "tail_entity_id": "T413"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R202",
              "head_entity_id": "T418",
              "tail_entity_id": "T414"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R203",
              "head_entity_id": "T417",
              "tail_entity_id": "T415"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "36",
      "paragraph": "吡格列酮对大血管事件影响的前瞻性临床试验(PROactive)是一项随机、双盲、安慰剂对照的临床研究，在5238例伴有心血管疾病的T2DM患者中评估吡格列酮的心血管安全性。受试者在常规治疗基础上联合吡格列酮或安慰剂治疗，平均随访时间为34.5个月。结果显示，与安慰剂组相比，吡格列酮组的首要复合事件终点(全因死亡、非致死性心肌梗死、卒中、ACS、冠状动脉或下肢动脉的血运重建、踝关节以上的下肢截肢)风险差异无统计学意义(HR 0.90，95%CI 0.80~1.02，P=0.095)，主要次级终点(全因死亡、非致死性心肌梗死或卒中)相对风险下降16%(P=0.027)。PROactive研究结束后继续随访7.8年发现，两组间在首要终点和主要次级终点方面比较，差异均无统计学意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "吡格列酮对大血管事件影响的前瞻性临床试验(PROactive)是一项随机、双盲、安慰剂对照的临床研究，在5238例伴有心血管疾病的T2DM患者中评估吡格列酮的心血管安全性。受试者在常规治疗基础上联合吡格列酮或安慰剂治疗，平均随访时间为34.5个月。结果显示，与安慰剂组相比，吡格列酮组的首要复合事件终点(全因死亡、非致死性心肌梗死、卒中、ACS、冠状动脉或下肢动脉的血运重建、踝关节以上的下肢截肢)风险差异无统计学意义(HR 0.90，95%CI 0.80~1.02，P=0.095)，主要次级终点(全因死亡、非致死性心肌梗死或卒中)相对风险下降16%(P=0.027)。",
          "start_idx": 0,
          "end_idx": 286,
          "entities": [
            {
              "entity_id": "T421",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T422",
              "entity": "大血管事件",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10
            },
            {
              "entity_id": "T423",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 5,
              "end_idx": 8
            },
            {
              "entity_id": "T424",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 64
            },
            {
              "entity_id": "T425",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 59,
              "end_idx": 62
            },
            {
              "entity_id": "T426",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 69
            },
            {
              "entity_id": "T427",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 65,
              "end_idx": 67
            },
            {
              "entity_id": "T428",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 78
            },
            {
              "entity_id": "T429",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 99,
              "end_idx": 103
            },
            {
              "entity_id": "T430",
              "entity": "吡格列酮",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 141
            },
            {
              "entity_id": "T431",
              "entity": "非致死性心肌梗死",
              "entity_type": "Disease",
              "start_idx": 157,
              "end_idx": 165
            },
            {
              "entity_id": "T432",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 157,
              "end_idx": 161
            },
            {
              "entity_id": "T433",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 161,
              "end_idx": 163
            },
            {
              "entity_id": "T434",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 166,
              "end_idx": 168
            },
            {
              "entity_id": "T435",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 169,
              "end_idx": 172
            },
            {
              "entity_id": "T436",
              "entity": "冠状动脉或下肢动脉的血运重建",
              "entity_type": "Operation",
              "start_idx": 173,
              "end_idx": 187
            },
            {
              "entity_id": "T437",
              "entity": "踝关节以上的下肢截肢",
              "entity_type": "Operation",
              "start_idx": 188,
              "end_idx": 198
            },
            {
              "entity_id": "T438",
              "entity": "非致死性心肌梗死",
              "entity_type": "Disease",
              "start_idx": 255,
              "end_idx": 263
            },
            {
              "entity_id": "T439",
              "entity": "非致死性",
              "entity_type": "Class",
              "start_idx": 255,
              "end_idx": 259
            },
            {
              "entity_id": "T440",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 259,
              "end_idx": 261
            },
            {
              "entity_id": "T441",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 264,
              "end_idx": 266
            },
            {
              "entity_id": "T442",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 79,
              "end_idx": 82
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R204",
              "head_entity_id": "T421",
              "tail_entity_id": "T422"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R205",
              "head_entity_id": "T423",
              "tail_entity_id": "T422"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R206",
              "head_entity_id": "T425",
              "tail_entity_id": "T424"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R207",
              "head_entity_id": "T428",
              "tail_entity_id": "T424"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R208",
              "head_entity_id": "T442",
              "tail_entity_id": "T424"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R209",
              "head_entity_id": "T427",
              "tail_entity_id": "T426"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R210",
              "head_entity_id": "T428",
              "tail_entity_id": "T426"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R211",
              "head_entity_id": "T442",
              "tail_entity_id": "T426"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R212",
              "head_entity_id": "T432",
              "tail_entity_id": "T431"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R213",
              "head_entity_id": "T433",
              "tail_entity_id": "T431"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R214",
              "head_entity_id": "T440",
              "tail_entity_id": "T438"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R215",
              "head_entity_id": "T439",
              "tail_entity_id": "T438"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "PROactive研究结束后继续随访7.8年发现，两组间在首要终点和主要次级终点方面比较，差异均无统计学意义。",
          "start_idx": 286,
          "end_idx": 341,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "37",
      "paragraph": "甘精胰岛素初始干预转归(ORIGIN)研究采用随机、双盲、2×2析因设计，纳入12537例有心血管高危因素的IFG、IGT或T2DM患者，随机分为甘精胰岛素或常规治疗，中位随访时间为6.2年。结果显示，与常规治疗组相比，甘精胰岛素治疗组3终点MACE的风险差异无统计学意义(HR 1.02，95%CI 0.94~1.11，P=0.63)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "甘精胰岛素初始干预转归(ORIGIN)研究采用随机、双盲、2×2析因设计，纳入12537例有心血管高危因素的IFG、IGT或T2DM患者，随机分为甘精胰岛素或常规治疗，中位随访时间为6.2年。",
          "start_idx": 0,
          "end_idx": 96,
          "entities": [
            {
              "entity_id": "T443",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T444",
              "entity": "IFG",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 57
            },
            {
              "entity_id": "T445",
              "entity": "IGT",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 61
            },
            {
              "entity_id": "T446",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 66
            },
            {
              "entity_id": "T447",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 62,
              "end_idx": 64
            },
            {
              "entity_id": "T448",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 73,
              "end_idx": 78
            },
            {
              "entity_id": "T450",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 46,
              "end_idx": 49
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R216",
              "head_entity_id": "T450",
              "tail_entity_id": "T444"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R217",
              "head_entity_id": "T448",
              "tail_entity_id": "T444"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R218",
              "head_entity_id": "T450",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R219",
              "head_entity_id": "T448",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R220",
              "head_entity_id": "T447",
              "tail_entity_id": "T446"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R221",
              "head_entity_id": "T450",
              "tail_entity_id": "T446"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R222",
              "head_entity_id": "T448",
              "tail_entity_id": "T446"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "结果显示，与常规治疗组相比，甘精胰岛素治疗组3终点MACE的风险差异无统计学意义(HR 1.02，95%CI 0.94~1.11，P=0.63)。",
          "start_idx": 96,
          "end_idx": 169,
          "entities": [
            {
              "entity_id": "T449",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 19
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "38",
      "paragraph": "在二肽基肽酶4(DPP-4)抑制剂中进行的3项随机、双盲、安慰剂对照的CVOT均显示，DPP-4抑制剂既不增加也不降低心血管事件发生风险。评估T2DM患者中西格列汀心血管安全性(TECOS)研究纳入14671例有心血管病史的T2DM患者，中位随访时间为3年。结果显示，在常规降糖治疗基上，与安慰剂组相比，西格列汀组首要心血管事件复合终点(3终点MACE+不稳定型心绞痛住院)的风险达到非劣效性标准(HR 0.98，95%CI 0.88~1.09)。且不增加心力衰竭住院风险。评价沙格列汀在糖尿病患者中的心血管结局(SAVOR-TIMI53)研究纳入16492例伴有心血管疾病或心血管危险因素的T2DM患者，中位随访时间为2.1年。结果显示，在常规降糖治疗基础上，与安慰剂组相比，沙格列汀组3终点MACE的风险达到非劣效性标准(HR 1.00，95%CI 0.89~1.12)，但心力衰竭住院相对风险增加27%(P=0.007)。阿格列汀与标准治疗在T2DM合并ACS患者中心血管结局比较(EXAMINE)研究在5380例既往15~90d内发生过ACS的T2DM患者中评估阿格列汀的心血管安全性，中位随访时间为18个月。结果显示，在常规降糖治疗基上，与安慰剂组相比，阿格列汀组3终点MACE的风险达到非劣效性标准(HR 0.96，单侧重复CI上限1.16)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "在二肽基肽酶4(DPP-4)抑制剂中进行的3项随机、双盲、安慰剂对照的CVOT均显示，DPP-4抑制剂既不增加也不降低心血管事件发生风险。评估T2DM患者中西格列汀心血管安全性(TECOS)研究纳入14671例有心血管病史的T2DM患者，中位随访时间为3年。结果显示，在常规降糖治疗基上，与安慰剂组相比，西格列汀组首要心血管事件复合终点(3终点MACE+不稳定型心绞痛住院)的风险达到非劣效性标准(HR 0.98，95%CI 0.88~1.09)。且不增加心力衰竭住院风险。评价沙格列汀在糖尿病患者中的心血管结局(SAVOR-TIMI53)研究纳入16492例伴有心血管疾病或心血管危险因素的T2DM患者，中位随访时间为2.1年。结果显示，在常规降糖治疗基础上，与安慰剂组相比，沙格列汀组3终点MACE的风险达到非劣效性标准(HR 1.00，95%CI 0.89~1.12)，但心力衰竭住院相对风险增加27%(P=0.007)。阿格列汀与标准治疗在T2DM合并ACS患者中心血管结局比较(EXAMINE)研究在5380例既往15~90d内发生过ACS的T2DM患者中评估阿格列汀的心血管安全性，中位随访时间为18个月。",
          "start_idx": 0,
          "end_idx": 509,
          "entities": [
            {
              "entity_id": "T451",
              "entity": "二肽基肽酶4(DPP-4)抑制剂",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 17
            },
            {
              "entity_id": "T452",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 51
            },
            {
              "entity_id": "T453",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 64
            },
            {
              "entity_id": "T454",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 59,
              "end_idx": 62
            },
            {
              "entity_id": "T455",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 71,
              "end_idx": 75
            },
            {
              "entity_id": "T456",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 71,
              "end_idx": 73
            },
            {
              "entity_id": "T457",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 82
            },
            {
              "entity_id": "T458",
              "entity": "心血管病",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 110
            },
            {
              "entity_id": "T459",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 106,
              "end_idx": 109
            },
            {
              "entity_id": "T460",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 112,
              "end_idx": 116
            },
            {
              "entity_id": "T461",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 112,
              "end_idx": 114
            },
            {
              "entity_id": "T462",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 152,
              "end_idx": 156
            },
            {
              "entity_id": "T463",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 159,
              "end_idx": 164
            },
            {
              "entity_id": "T464",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 159,
              "end_idx": 162
            },
            {
              "entity_id": "T465",
              "entity": "不稳定型心绞痛",
              "entity_type": "Disease",
              "start_idx": 177,
              "end_idx": 184
            },
            {
              "entity_id": "T466",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 181,
              "end_idx": 182
            },
            {
              "entity_id": "T467",
              "entity": "不稳定型",
              "entity_type": "Class",
              "start_idx": 177,
              "end_idx": 181
            },
            {
              "entity_id": "T468",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 228,
              "end_idx": 232
            },
            {
              "entity_id": "T469",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 228,
              "end_idx": 229
            },
            {
              "entity_id": "T470",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 239,
              "end_idx": 243
            },
            {
              "entity_id": "T471",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 244,
              "end_idx": 247
            },
            {
              "entity_id": "T472",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 282,
              "end_idx": 287
            },
            {
              "entity_id": "T473",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 282,
              "end_idx": 285
            },
            {
              "entity_id": "T474",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 296,
              "end_idx": 300
            },
            {
              "entity_id": "T475",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 296,
              "end_idx": 298
            },
            {
              "entity_id": "T476",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 339,
              "end_idx": 343
            },
            {
              "entity_id": "T477",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 389,
              "end_idx": 393
            },
            {
              "entity_id": "T478",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 389,
              "end_idx": 390
            },
            {
              "entity_id": "T479",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 414,
              "end_idx": 418
            },
            {
              "entity_id": "T480",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 424,
              "end_idx": 428
            },
            {
              "entity_id": "T481",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 424,
              "end_idx": 426
            },
            {
              "entity_id": "T482",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 430,
              "end_idx": 433
            },
            {
              "entity_id": "T483",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 472,
              "end_idx": 475
            },
            {
              "entity_id": "T484",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 476,
              "end_idx": 480
            },
            {
              "entity_id": "T485",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 476,
              "end_idx": 478
            },
            {
              "entity_id": "T486",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 485,
              "end_idx": 489
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R223",
              "head_entity_id": "T452",
              "tail_entity_id": "T453"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R224",
              "head_entity_id": "T454",
              "tail_entity_id": "T453"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R225",
              "head_entity_id": "T456",
              "tail_entity_id": "T455"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R226",
              "head_entity_id": "T457",
              "tail_entity_id": "T455"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R227",
              "head_entity_id": "T459",
              "tail_entity_id": "T458"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R228",
              "head_entity_id": "T461",
              "tail_entity_id": "T460"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R229",
              "head_entity_id": "T462",
              "tail_entity_id": "T463"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R230",
              "head_entity_id": "T464",
              "tail_entity_id": "T463"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R231",
              "head_entity_id": "T466",
              "tail_entity_id": "T465"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R232",
              "head_entity_id": "T467",
              "tail_entity_id": "T465"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R233",
              "head_entity_id": "T469",
              "tail_entity_id": "T468"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R234",
              "head_entity_id": "T470",
              "tail_entity_id": "T471"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R235",
              "head_entity_id": "T473",
              "tail_entity_id": "T472"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R236",
              "head_entity_id": "T475",
              "tail_entity_id": "T474"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R237",
              "head_entity_id": "T478",
              "tail_entity_id": "T477"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R238",
              "head_entity_id": "T479",
              "tail_entity_id": "T480"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R239",
              "head_entity_id": "T479",
              "tail_entity_id": "T482"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R240",
              "head_entity_id": "T481",
              "tail_entity_id": "T480"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R241",
              "head_entity_id": "T486",
              "tail_entity_id": "T483"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R242",
              "head_entity_id": "T486",
              "tail_entity_id": "T484"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R243",
              "head_entity_id": "T485",
              "tail_entity_id": "T484"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "结果显示，在常规降糖治疗基上，与安慰剂组相比，阿格列汀组3终点MACE的风险达到非劣效性标准(HR 0.96，单侧重复CI上限1.16)。",
          "start_idx": 509,
          "end_idx": 578,
          "entities": [
            {
              "entity_id": "T487",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "39",
      "paragraph": "利司那肽治疗T2DM合并ACS患者的心血管事件评估(ELIXA)研究是一项随机、双盲、安慰剂对照的临床试验，纳入6068例在既往180d内发生过ACS的T2DM患者，中位随访时间为25个月。结果显示，在常规降糖治疗基础上，与安慰剂组相比，利司那肽组首要心血管事件复合终点(3终点MACE+不稳定性心绞痛住院)的风险达到非劣效性标准( HR 1.02，95%CI 0.89~1.17)，且不增加心力衰竭住院风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "利司那肽治疗T2DM合并ACS患者的心血管事件评估(ELIXA)研究是一项随机、双盲、安慰剂对照的临床试验，纳入6068例在既往180d内发生过ACS的T2DM患者，中位随访时间为25个月。结果显示，在常规降糖治疗基础上，与安慰剂组相比，利司那肽组首要心血管事件复合终点(3终点MACE+不稳定性心绞痛住院)的风险达到非劣效性标准( HR 1.02，95%CI 0.89~1.17)，且不增加心力衰竭住院风险。",
          "start_idx": 0,
          "end_idx": 205,
          "entities": [
            {
              "entity_id": "T488",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T489",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 10
            },
            {
              "entity_id": "T490",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 6,
              "end_idx": 8
            },
            {
              "entity_id": "T491",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 15
            },
            {
              "entity_id": "T492",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23
            },
            {
              "entity_id": "T493",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 18,
              "end_idx": 21
            },
            {
              "entity_id": "T494",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 75
            },
            {
              "entity_id": "T495",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 76,
              "end_idx": 80
            },
            {
              "entity_id": "T496",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 76,
              "end_idx": 78
            },
            {
              "entity_id": "T497",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 123
            },
            {
              "entity_id": "T498",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 126,
              "end_idx": 131
            },
            {
              "entity_id": "T499",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 126,
              "end_idx": 129
            },
            {
              "entity_id": "T500",
              "entity": "不稳定性心绞痛",
              "entity_type": "Disease",
              "start_idx": 144,
              "end_idx": 151
            },
            {
              "entity_id": "T501",
              "entity": "不稳定性",
              "entity_type": "Class",
              "start_idx": 144,
              "end_idx": 148
            },
            {
              "entity_id": "T502",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 148,
              "end_idx": 149
            },
            {
              "entity_id": "T503",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 196,
              "end_idx": 200
            },
            {
              "entity_id": "T504",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 196,
              "end_idx": 197
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R244",
              "head_entity_id": "T488",
              "tail_entity_id": "T489"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R245",
              "head_entity_id": "T488",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R246",
              "head_entity_id": "T490",
              "tail_entity_id": "T489"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R247",
              "head_entity_id": "T493",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R248",
              "head_entity_id": "T496",
              "tail_entity_id": "T495"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R249",
              "head_entity_id": "T497",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R250",
              "head_entity_id": "T499",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R251",
              "head_entity_id": "T501",
              "tail_entity_id": "T500"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R252",
              "head_entity_id": "T502",
              "tail_entity_id": "T500"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R253",
              "head_entity_id": "T504",
              "tail_entity_id": "T503"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "40",
      "paragraph": "上述研究数据表明，罗格列酮、毗格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽的心血管效应为中性，既不增加也不降低心血管事件发生风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "上述研究数据表明，罗格列酮、毗格列酮、甘精胰岛素、西格列汀、沙格列汀、阿格列汀及利司那肽的心血管效应为中性，既不增加也不降低心血管事件发生风险。",
          "start_idx": 0,
          "end_idx": 72,
          "entities": [
            {
              "entity_id": "T505",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13
            },
            {
              "entity_id": "T506",
              "entity": "毗格列酮",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18
            },
            {
              "entity_id": "T507",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 24
            },
            {
              "entity_id": "T508",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 29
            },
            {
              "entity_id": "T509",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 34
            },
            {
              "entity_id": "T510",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 39
            },
            {
              "entity_id": "T511",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 44
            },
            {
              "entity_id": "T512",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 67
            },
            {
              "entity_id": "T513",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 62,
              "end_idx": 65
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R254",
              "head_entity_id": "T513",
              "tail_entity_id": "T512"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "41",
      "paragraph": "3.其他降糖药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.其他降糖药物",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "42",
      "paragraph": "(1)目前缺少在T2DM患者中评估心血管安全性的CVOT证据的降糖药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)目前缺少在T2DM患者中评估心血管安全性的CVOT证据的降糖药物",
          "start_idx": 0,
          "end_idx": 35,
          "entities": [
            {
              "entity_id": "T514",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T515",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 8,
              "end_idx": 10
            },
            {
              "entity_id": "T516",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 17,
              "end_idx": 20
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R255",
              "head_entity_id": "T515",
              "tail_entity_id": "T514"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R256",
              "head_entity_id": "T516",
              "tail_entity_id": "T514"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "43",
      "paragraph": "对于那些未进行CVOT的传统降糖药物而言，其心血管安全性证据主要源自针对降糖治疗策略的RCT研究数据或基于针对降糖疗效的多项RCTs的荟萃分析结果，这些药物包括SUs、格列奈类、维格列汀及大部分胰岛素制剂。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于那些未进行CVOT的传统降糖药物而言，其心血管安全性证据主要源自针对降糖治疗策略的RCT研究数据或基于针对降糖疗效的多项RCTs的荟萃分析结果，这些药物包括SUs、格列奈类、维格列汀及大部分胰岛素制剂。",
          "start_idx": 0,
          "end_idx": 103,
          "entities": [
            {
              "entity_id": "T517",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 80,
              "end_idx": 83
            },
            {
              "entity_id": "T518",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 88
            },
            {
              "entity_id": "T519",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 93
            },
            {
              "entity_id": "T520",
              "entity": "胰岛素制剂",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 102
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "44",
      "paragraph": "47项RCTs研究的荟萃分析显示，与安慰剂或活性对照药相比，SUs不增加T2DM患者全因死亡、心血管死亡、心肌梗死及卒中的风险.。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "47项RCTs研究的荟萃分析显示，与安慰剂或活性对照药相比，SUs不增加T2DM患者全因死亡、心血管死亡、心肌梗死及卒中的风险.。",
          "start_idx": 0,
          "end_idx": 65,
          "entities": [
            {
              "entity_id": "T521",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 33
            },
            {
              "entity_id": "T522",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 40
            },
            {
              "entity_id": "T523",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 36,
              "end_idx": 38
            },
            {
              "entity_id": "T524",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 52
            },
            {
              "entity_id": "T525",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T526",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 60
            },
            {
              "entity_id": "T527",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 47,
              "end_idx": 50
            },
            {
              "entity_id": "T528",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 53,
              "end_idx": 55
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R257",
              "head_entity_id": "T521",
              "tail_entity_id": "T522"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R258",
              "head_entity_id": "T523",
              "tail_entity_id": "T522"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R259",
              "head_entity_id": "T527",
              "tail_entity_id": "T524"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R260",
              "head_entity_id": "T528",
              "tail_entity_id": "T525"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "45",
      "paragraph": "那格列奈和缬沙坦在IGT人群中的结局研究(NAVIGATOR)显示，在有心血管事件病史或心血管危险因素的IGT患者中，与安慰剂相比，那格列奈治疗5年后，首要心血管事件复合终点(3终点MACE+心力衰竭住院)风险差异无统计学意义( HR 0.94，95%CI 0.82~1.09，P=0.43)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "那格列奈和缬沙坦在IGT人群中的结局研究(NAVIGATOR)显示，在有心血管事件病史或心血管危险因素的IGT患者中，与安慰剂相比，那格列奈治疗5年后，首要心血管事件复合终点(3终点MACE+心力衰竭住院)风险差异无统计学意义( HR 0.94，95%CI 0.82~1.09，P=0.43)。",
          "start_idx": 0,
          "end_idx": 147,
          "entities": [
            {
              "entity_id": "T529",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T530",
              "entity": "缬沙坦",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8
            },
            {
              "entity_id": "T531",
              "entity": "IGT",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12
            },
            {
              "entity_id": "T532",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 41
            },
            {
              "entity_id": "T533",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 36,
              "end_idx": 39
            },
            {
              "entity_id": "T534",
              "entity": "IGT",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 55
            },
            {
              "entity_id": "T535",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 70
            },
            {
              "entity_id": "T536",
              "entity": "5年",
              "entity_type": "Duration",
              "start_idx": 72,
              "end_idx": 74
            },
            {
              "entity_id": "T537",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 78,
              "end_idx": 83
            },
            {
              "entity_id": "T538",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 78,
              "end_idx": 81
            },
            {
              "entity_id": "T539",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 96,
              "end_idx": 100
            },
            {
              "entity_id": "T540",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 96,
              "end_idx": 97
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R261",
              "head_entity_id": "T529",
              "tail_entity_id": "T531"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R262",
              "head_entity_id": "T530",
              "tail_entity_id": "T531"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R263",
              "head_entity_id": "T533",
              "tail_entity_id": "T532"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R264",
              "head_entity_id": "T536",
              "tail_entity_id": "T535"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R265",
              "head_entity_id": "T538",
              "tail_entity_id": "T537"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R266",
              "head_entity_id": "T540",
              "tail_entity_id": "T539"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "46",
      "paragraph": "25项Ⅲ期临床试验的荟萃分析显示，与安慰剂或活性对照药相比，维格列汀不增加T2DM患者心脑血管事件风险，其中50mg/d组的相对风险为0.88(95%CI 0.37~2.11)、100mg/d组的相对风险0.84(95%CI 0.62~1.14).。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "25项Ⅲ期临床试验的荟萃分析显示，与安慰剂或活性对照药相比，维格列汀不增加T2DM患者心脑血管事件风险，其中50mg/d组的相对风险为0.88(95%CI 0.37~2.11)、100mg/d组的相对风险0.84(95%CI 0.62~1.14).。",
          "start_idx": 0,
          "end_idx": 125,
          "entities": [
            {
              "entity_id": "T541",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 34
            },
            {
              "entity_id": "T542",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 41
            },
            {
              "entity_id": "T543",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 37,
              "end_idx": 39
            },
            {
              "entity_id": "T544",
              "entity": "心脑血管事件",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 49
            },
            {
              "entity_id": "T545",
              "entity": "心脑血管",
              "entity_type": "Anatomy",
              "start_idx": 43,
              "end_idx": 47
            },
            {
              "entity_id": "T546",
              "entity": "50mg/d",
              "entity_type": "Amount",
              "start_idx": 54,
              "end_idx": 60
            },
            {
              "entity_id": "T547",
              "entity": "100mg/d",
              "entity_type": "Amount",
              "start_idx": 89,
              "end_idx": 96
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R267",
              "head_entity_id": "T546",
              "tail_entity_id": "T541"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R268",
              "head_entity_id": "T547",
              "tail_entity_id": "T541"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R269",
              "head_entity_id": "T541",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R270",
              "head_entity_id": "T543",
              "tail_entity_id": "T542"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R271",
              "head_entity_id": "T545",
              "tail_entity_id": "T544"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "47",
      "paragraph": "T2DM心血管结局(HEART2D)研究显示，在急性心肌梗死后的T2DM患者中，餐时胰岛素或基础胰岛素治疗2.7年后，首要心血管事件复合终点(3终点MACE+冠状动脉血运重建或ACS住院)的风险相似( HR 0.98，95%CI 0.88~1.21)。事后亚组分析提示，在年龄>65.7岁亚组中，与基础胰岛素组相比，餐时胰岛素组首次心血管事件的发生风险更低(HR 0.69，95%CI 0.49~0.96)，表现为发生比例更低、时间更晚。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "T2DM心血管结局(HEART2D)研究显示，在急性心肌梗死后的T2DM患者中，餐时胰岛素或基础胰岛素治疗2.7年后，首要心血管事件复合终点(3终点MACE+冠状动脉血运重建或ACS住院)的风险相似( HR 0.98，95%CI 0.88~1.21)。事后亚组分析提示，在年龄>65.7岁亚组中，与基础胰岛素组相比，餐时胰岛素组首次心血管事件的发生风险更低(HR 0.69，95%CI 0.49~0.96)，表现为发生比例更低、时间更晚。",
          "start_idx": 0,
          "end_idx": 219,
          "entities": [
            {
              "entity_id": "T548",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T549",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2
            },
            {
              "entity_id": "T550",
              "entity": "急性心肌梗死",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 30
            },
            {
              "entity_id": "T551",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26
            },
            {
              "entity_id": "T552",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 26,
              "end_idx": 28
            },
            {
              "entity_id": "T553",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 36
            },
            {
              "entity_id": "T554",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34
            },
            {
              "entity_id": "T555",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 45
            },
            {
              "entity_id": "T556",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 51
            },
            {
              "entity_id": "T557",
              "entity": "2.7年",
              "entity_type": "Duration",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T558",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 7
            },
            {
              "entity_id": "T559",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 66
            },
            {
              "entity_id": "T560",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 61,
              "end_idx": 64
            },
            {
              "entity_id": "T561",
              "entity": "冠状动脉血运重建",
              "entity_type": "Operation",
              "start_idx": 79,
              "end_idx": 87
            },
            {
              "entity_id": "T562",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 91
            },
            {
              "entity_id": "T563",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 149,
              "end_idx": 154
            },
            {
              "entity_id": "T564",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 158,
              "end_idx": 163
            },
            {
              "entity_id": "T565",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 166,
              "end_idx": 171
            },
            {
              "entity_id": "T566",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 166,
              "end_idx": 169
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R272",
              "head_entity_id": "T549",
              "tail_entity_id": "T548"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R273",
              "head_entity_id": "T558",
              "tail_entity_id": "T548"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R274",
              "head_entity_id": "T551",
              "tail_entity_id": "T550"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R275",
              "head_entity_id": "T552",
              "tail_entity_id": "T550"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R276",
              "head_entity_id": "T554",
              "tail_entity_id": "T553"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R277",
              "head_entity_id": "T555",
              "tail_entity_id": "T553"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R278",
              "head_entity_id": "T556",
              "tail_entity_id": "T553"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R279",
              "head_entity_id": "T557",
              "tail_entity_id": "T555"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R280",
              "head_entity_id": "T557",
              "tail_entity_id": "T556"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R281",
              "head_entity_id": "T560",
              "tail_entity_id": "T559"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R282",
              "head_entity_id": "T566",
              "tail_entity_id": "T565"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "48",
      "paragraph": "(2)CVOT尚在进行中的降糖药物",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)CVOT尚在进行中的降糖药物",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "49",
      "paragraph": "目前，正在进行CVOT的降糖药物包括阿卡波糖、利格列汀、艾塞那肽(周制剂)、度拉唐肽、阿必鲁肽、达格列净、坎格列净及德谷胰岛素。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前，正在进行CVOT的降糖药物包括阿卡波糖、利格列汀、艾塞那肽(周制剂)、度拉唐肽、阿必鲁肽、达格列净、坎格列净及德谷胰岛素。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T567",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22
            },
            {
              "entity_id": "T568",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27
            },
            {
              "entity_id": "T569",
              "entity": "艾塞那肽(周制剂)",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 37
            },
            {
              "entity_id": "T570",
              "entity": "度拉唐肽",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42
            },
            {
              "entity_id": "T571",
              "entity": "阿必鲁肽",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 47
            },
            {
              "entity_id": "T572",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 52
            },
            {
              "entity_id": "T573",
              "entity": "坎格列净",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T574",
              "entity": "德谷胰岛素",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 63
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "50",
      "paragraph": "(二)降糖药物的用药原则",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(二)降糖药物的用药原则",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "51",
      "paragraph": "降糖治疗的目标不仅仅是单纯控制血糖，更重要的是减少糖尿病并发症（特别是心血管事件）、降低死亡风险，从而改善患者的远期预后。生活方式干预是T2DM患者降糖治疗的基础性措施，应贯穿于降糖治疗的始终。如果单纯生活方式干预不能使血糖达标，应开始药物治疗。对于合并ASCVD的T2DM患者，尤应注意心血管安全性问题，并且优先考虑选择具有心血管获益证据的降糖药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "降糖治疗的目标不仅仅是单纯控制血糖，更重要的是减少糖尿病并发症（特别是心血管事件）、降低死亡风险，从而改善患者的远期预后。生活方式干预是T2DM患者降糖治疗的基础性措施，应贯穿于降糖治疗的始终。如果单纯生活方式干预不能使血糖达标，应开始药物治疗。对于合并ASCVD的T2DM患者，尤应注意心血管安全性问题，并且优先考虑选择具有心血管获益证据的降糖药物。",
          "start_idx": 0,
          "end_idx": 176,
          "entities": [
            {
              "entity_id": "T575",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 15,
              "end_idx": 17
            },
            {
              "entity_id": "T576",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 28
            },
            {
              "entity_id": "T577",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 40
            },
            {
              "entity_id": "T578",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 35,
              "end_idx": 38
            },
            {
              "entity_id": "T579",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 61,
              "end_idx": 67
            },
            {
              "entity_id": "T580",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 72
            },
            {
              "entity_id": "T581",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 68,
              "end_idx": 70
            },
            {
              "entity_id": "T582",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 101,
              "end_idx": 107
            },
            {
              "entity_id": "T583",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 110,
              "end_idx": 112
            },
            {
              "entity_id": "T584",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 112,
              "end_idx": 114
            },
            {
              "entity_id": "T585",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 127,
              "end_idx": 132
            },
            {
              "entity_id": "T586",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 133,
              "end_idx": 137
            },
            {
              "entity_id": "T587",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 133,
              "end_idx": 135
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R283",
              "head_entity_id": "T578",
              "tail_entity_id": "T577"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R284",
              "head_entity_id": "T579",
              "tail_entity_id": "T580"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R285",
              "head_entity_id": "T581",
              "tail_entity_id": "T580"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R286",
              "head_entity_id": "T587",
              "tail_entity_id": "T586"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "52",
      "paragraph": "1.一线治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.一线治疗",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "53",
      "paragraph": "大多数国内外指南均推荐二甲双胍作为T2DM",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "大多数国内外指南均推荐二甲双胍作为T2DM",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T588",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15
            },
            {
              "entity_id": "T589",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 21
            },
            {
              "entity_id": "T590",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 17,
              "end_idx": 19
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R287",
              "head_entity_id": "T588",
              "tail_entity_id": "T589"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R288",
              "head_entity_id": "T590",
              "tail_entity_id": "T589"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "54",
      "paragraph": "患者单药治疗的一线首选药物和联合治疗的基本用药，如无禁忌证且能够耐受，二甲双胍应一直保留在T2DM患者的降糖治疗方案中。若存在禁忌证或无法耐受，建议视患者的具体情况考虑选择具有心血管保护或中性的降糖药物.",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "患者单药治疗的一线首选药物和联合治疗的基本用药，如无禁忌证且能够耐受，二甲双胍应一直保留在T2DM患者的降糖治疗方案中。",
          "start_idx": 0,
          "end_idx": 60,
          "entities": [
            {
              "entity_id": "T591",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 39
            },
            {
              "entity_id": "T592",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 49
            },
            {
              "entity_id": "T593",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 45,
              "end_idx": 47
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R289",
              "head_entity_id": "T591",
              "tail_entity_id": "T592"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R290",
              "head_entity_id": "T593",
              "tail_entity_id": "T592"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "若存在禁忌证或无法耐受，建议视患者的具体情况考虑选择具有心血管保护或中性的降糖药物.",
          "start_idx": 60,
          "end_idx": 102,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "55",
      "paragraph": "2.联合治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.联合治疗",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "56",
      "paragraph": "若一线降药物单药治疗3个月不能使血糖控制达标，需考虑两种降糖药物联合治疗。根据患者的不同情况，选择个体化的联合用药方案。对于T2DM合并ASCVD患者，可优先考虑联合具有明确心血管获益证据的降常药物(如利拉鲁肽或恩格列净)治疗，",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "若一线降药物单药治疗3个月不能使血糖控制达标，需考虑两种降糖药物联合治疗。根据患者的不同情况，选择个体化的联合用药方案。对于T2DM合并ASCVD患者，可优先考虑联合具有明确心血管获益证据的降常药物(如利拉鲁肽或恩格列净)治疗，",
          "start_idx": 0,
          "end_idx": 114,
          "entities": [
            {
              "entity_id": "T594",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 18
            },
            {
              "entity_id": "T595",
              "entity": "控制达标",
              "entity_type": "Test_Value",
              "start_idx": 18,
              "end_idx": 22
            },
            {
              "entity_id": "T596",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 66
            },
            {
              "entity_id": "T597",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 62,
              "end_idx": 64
            },
            {
              "entity_id": "T598",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 73
            },
            {
              "entity_id": "T599",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 101,
              "end_idx": 105
            },
            {
              "entity_id": "T600",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 106,
              "end_idx": 110
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R291",
              "head_entity_id": "T597",
              "tail_entity_id": "T596"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R292",
              "head_entity_id": "T599",
              "tail_entity_id": "T596"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R293",
              "head_entity_id": "T600",
              "tail_entity_id": "T596"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R294",
              "head_entity_id": "T599",
              "tail_entity_id": "T598"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R295",
              "head_entity_id": "T600",
              "tail_entity_id": "T598"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "57",
      "paragraph": "以最大限度降低患者心血管事件和死亡的风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "以最大限度降低患者心血管事件和死亡的风险。",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T601",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14
            },
            {
              "entity_id": "T602",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 9,
              "end_idx": 12
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R296",
              "head_entity_id": "T602",
              "tail_entity_id": "T601"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "58",
      "paragraph": "若两种降糖药物联合治疗3个月不能使患者血糖控制达标，可考虑联合第3种降糖药物或者联合胰岛素治疗.。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "若两种降糖药物联合治疗3个月不能使患者血糖控制达标，可考虑联合第3种降糖药物或者联合胰岛素治疗.。",
          "start_idx": 0,
          "end_idx": 49,
          "entities": [
            {
              "entity_id": "T603",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 19,
              "end_idx": 21
            },
            {
              "entity_id": "T604",
              "entity": "控制达标",
              "entity_type": "Test_Value",
              "start_idx": 21,
              "end_idx": 25
            },
            {
              "entity_id": "T605",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 45
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "59",
      "paragraph": "(三)降糖治疗的药物选择",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(三)降糖治疗的药物选择",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "60",
      "paragraph": "1.非胰岛素降糖药",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.非胰岛素降糖药",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T606",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 6
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "61",
      "paragraph": "表2总结了常用非胰岛素降糖药的作用机制、使用方法、降糖疗效、低血糖风险、对体重的影响、注意事项等主要信息。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "表2总结了常用非胰岛素降糖药的作用机制、使用方法、降糖疗效、低血糖风险、对体重的影响、注意事项等主要信息。",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T607",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 11
            },
            {
              "entity_id": "T608",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 30,
              "end_idx": 33
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "62",
      "paragraph": "(四)其他特殊情况",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(四)其他特殊情况",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "63",
      "paragraph": "1.ASCVD急性期",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.ASCVD急性期",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T609",
              "entity": "ASCVD急性期",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 10
            },
            {
              "entity_id": "T610",
              "entity": "急性期",
              "entity_type": "Class",
              "start_idx": 7,
              "end_idx": 10
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R297",
              "head_entity_id": "T610",
              "tail_entity_id": "T609"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "64",
      "paragraph": "对于处在ASCVD急性期(如ACS、缺血性卒中急性期、冠状动脉血运重建围手术期等)的T2DM患者，其降糖治疗方案需要充分考虑疾病特点、机体应激状况以及严格降糖治疗的获益/风险比。对于合并ACS的患者，若血糖>10.0mmol/L，可采用以胰岛素为基础的降糖治疗方案，使血糖水平控制在7.8~10.0mmol/L，同时注意避免发生低血糖。对于接受经皮冠状动脉介人治疗(PCI)的患者，使用对比剂前可以不停用二甲双胍，但应密切监测肾功能，造影后应连续两日检验血清肌酐(Scr)。若Scr值比造影前上升26.5μmol/L，则应考虑对比剂肾病发生，应立即停用二甲双胍，直至肾功能恢复至基础水平，方可重新开始二甲双胍治疗。目前尚无充分的证据提示，不同降糖药物对接受PCI治疗患者的预后存在不同的影响。对于接受冠状动脉旁路移植术(CABG)的患者，围手术期不",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于处在ASCVD急性期(如ACS、缺血性卒中急性期、冠状动脉血运重建围手术期等)的T2DM患者，其降糖治疗方案需要充分考虑疾病特点、机体应激状况以及严格降糖治疗的获益/风险比。对于合并ACS的患者，若血糖>10.0mmol/L，可采用以胰岛素为基础的降糖治疗方案，使血糖水平控制在7.8~10.0mmol/L，同时注意避免发生低血糖。对于接受经皮冠状动脉介人治疗(PCI)的患者，使用对比剂前可以不停用二甲双胍，但应密切监测肾功能，造影后应连续两日检验血清肌酐(Scr)。若Scr值比造影前上升26.5μmol/L，则应考虑对比剂肾病发生，应立即停用二甲双胍，直至肾功能恢复至基础水平，方可重新开始二甲双胍治疗。",
          "start_idx": 0,
          "end_idx": 307,
          "entities": [
            {
              "entity_id": "T611",
              "entity": "ASCVD急性期",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 12
            },
            {
              "entity_id": "T612",
              "entity": "急性期",
              "entity_type": "Class",
              "start_idx": 9,
              "end_idx": 12
            },
            {
              "entity_id": "T613",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 17
            },
            {
              "entity_id": "T614",
              "entity": "缺血性卒中急性期",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 26
            },
            {
              "entity_id": "T615",
              "entity": "急性期",
              "entity_type": "Class",
              "start_idx": 23,
              "end_idx": 26
            },
            {
              "entity_id": "T616",
              "entity": "冠状动脉血运重建",
              "entity_type": "Operation",
              "start_idx": 27,
              "end_idx": 35
            },
            {
              "entity_id": "T617",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 46
            },
            {
              "entity_id": "T618",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 42,
              "end_idx": 44
            },
            {
              "entity_id": "T619",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 93,
              "end_idx": 96
            },
            {
              "entity_id": "T620",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 101,
              "end_idx": 103
            },
            {
              "entity_id": "T621",
              "entity": ">10.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 103,
              "end_idx": 114
            },
            {
              "entity_id": "T622",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 122
            },
            {
              "entity_id": "T623",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 134,
              "end_idx": 136
            },
            {
              "entity_id": "T624",
              "entity": "7.8~10.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 141,
              "end_idx": 155
            },
            {
              "entity_id": "T625",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 164,
              "end_idx": 167
            },
            {
              "entity_id": "T626",
              "entity": "经皮冠状动脉介人治疗(PCI)",
              "entity_type": "Operation",
              "start_idx": 172,
              "end_idx": 187
            },
            {
              "entity_id": "T627",
              "entity": "对比剂",
              "entity_type": "Drug",
              "start_idx": 193,
              "end_idx": 196
            },
            {
              "entity_id": "T628",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 202,
              "end_idx": 206
            },
            {
              "entity_id": "T629",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 213,
              "end_idx": 216
            },
            {
              "entity_id": "T630",
              "entity": "造影",
              "entity_type": "Test",
              "start_idx": 217,
              "end_idx": 219
            },
            {
              "entity_id": "T631",
              "entity": "血清肌酐(Scr)",
              "entity_type": "Test_items",
              "start_idx": 227,
              "end_idx": 236
            },
            {
              "entity_id": "T632",
              "entity": "Scr",
              "entity_type": "Test_items",
              "start_idx": 238,
              "end_idx": 241
            },
            {
              "entity_id": "T633",
              "entity": "上升26.5μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 246,
              "end_idx": 258
            },
            {
              "entity_id": "T634",
              "entity": "造影",
              "entity_type": "Test",
              "start_idx": 243,
              "end_idx": 245
            },
            {
              "entity_id": "T635",
              "entity": "对比剂",
              "entity_type": "Drug",
              "start_idx": 263,
              "end_idx": 266
            },
            {
              "entity_id": "T636",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 266,
              "end_idx": 268
            },
            {
              "entity_id": "T637",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 266,
              "end_idx": 267
            },
            {
              "entity_id": "T638",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 276,
              "end_idx": 280
            },
            {
              "entity_id": "T639",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 283,
              "end_idx": 286
            },
            {
              "entity_id": "T640",
              "entity": "恢复至基础水平",
              "entity_type": "Test_Value",
              "start_idx": 286,
              "end_idx": 293
            },
            {
              "entity_id": "T641",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 300,
              "end_idx": 304
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R298",
              "head_entity_id": "T612",
              "tail_entity_id": "T611"
            },
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R299",
              "head_entity_id": "T616",
              "tail_entity_id": "T611"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R300",
              "head_entity_id": "T615",
              "tail_entity_id": "T614"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R301",
              "head_entity_id": "T618",
              "tail_entity_id": "T617"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R302",
              "head_entity_id": "T620",
              "tail_entity_id": "T619"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R303",
              "head_entity_id": "T622",
              "tail_entity_id": "T619"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R304",
              "head_entity_id": "T623",
              "tail_entity_id": "T619"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R305",
              "head_entity_id": "T632",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R306",
              "head_entity_id": "T634",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R307",
              "head_entity_id": "T635",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R308",
              "head_entity_id": "T637",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R309",
              "head_entity_id": "T639",
              "tail_entity_id": "T636"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R310",
              "head_entity_id": "T641",
              "tail_entity_id": "T636"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "目前尚无充分的证据提示，不同降糖药物对接受PCI治疗患者的预后存在不同的影响。",
          "start_idx": 307,
          "end_idx": 346,
          "entities": [
            {
              "entity_id": "T642",
              "entity": "PCI",
              "entity_type": "Operation",
              "start_idx": 21,
              "end_idx": 24
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "对于接受冠状动脉旁路移植术(CABG)的患者，围手术期不",
          "start_idx": 346,
          "end_idx": 374,
          "entities": [
            {
              "entity_id": "T643",
              "entity": "冠状动脉旁路移植术(CABG)",
              "entity_type": "Operation",
              "start_idx": 4,
              "end_idx": 19
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "65",
      "paragraph": "推荐口服降糖药，应使用胰岛素治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐口服降糖药，应使用胰岛素治疗。",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [
            {
              "entity_id": "T644",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 14
            },
            {
              "entity_id": "T645",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 2,
              "end_idx": 4
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "66",
      "paragraph": "2.心力衰竭",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.心力衰竭",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [
            {
              "entity_id": "T646",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T647",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R311",
              "head_entity_id": "T647",
              "tail_entity_id": "T646"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "67",
      "paragraph": "T2DM和ASCVD患者常合并心力衰竭。对于合并心力衰竭的T2DM患者，制定降糖治疗方案时，应关注某些降糖药物对心力衰竭的潜在不良影响。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "T2DM和ASCVD患者常合并心力衰竭。对于合并心力衰竭的T2DM患者，制定降糖治疗方案时，应关注某些降糖药物对心力衰竭的潜在不良影响。",
          "start_idx": 0,
          "end_idx": 68,
          "entities": [
            {
              "entity_id": "T648",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T649",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2
            },
            {
              "entity_id": "T650",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10
            },
            {
              "entity_id": "T651",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 19
            },
            {
              "entity_id": "T652",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 15,
              "end_idx": 16
            },
            {
              "entity_id": "T653",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 28
            },
            {
              "entity_id": "T654",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 24,
              "end_idx": 25
            },
            {
              "entity_id": "T655",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 33
            },
            {
              "entity_id": "T656",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 29,
              "end_idx": 31
            },
            {
              "entity_id": "T657",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 60
            },
            {
              "entity_id": "T658",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 56,
              "end_idx": 57
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R312",
              "head_entity_id": "T649",
              "tail_entity_id": "T648"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R313",
              "head_entity_id": "T652",
              "tail_entity_id": "T651"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R314",
              "head_entity_id": "T654",
              "tail_entity_id": "T653"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R315",
              "head_entity_id": "T656",
              "tail_entity_id": "T655"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R316",
              "head_entity_id": "T658",
              "tail_entity_id": "T657"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "68",
      "paragraph": "二甲双胍：在定期检查心、肾功能的情况下，稳定期的慢性心力衰竭患者可以服用二甲双胍，但因存在乳酸性酸中毒的潜在风险，急性、病情不稳定或住院的心力衰竭患者禁用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍：在定期检查心、肾功能的情况下，稳定期的慢性心力衰竭患者可以服用二甲双胍，但因存在乳酸性酸中毒的潜在风险，急性、病情不稳定或住院的心力衰竭患者禁用。",
          "start_idx": 0,
          "end_idx": 78,
          "entities": [
            {
              "entity_id": "T659",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T660",
              "entity": "心、肾功能",
              "entity_type": "Test",
              "start_idx": 10,
              "end_idx": 15
            },
            {
              "entity_id": "T661",
              "entity": "慢性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 30
            },
            {
              "entity_id": "T662",
              "entity": "慢性",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26
            },
            {
              "entity_id": "T663",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 26,
              "end_idx": 27
            },
            {
              "entity_id": "T664",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 36,
              "end_idx": 40
            },
            {
              "entity_id": "T665",
              "entity": "乳酸性酸中毒",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 51
            },
            {
              "entity_id": "T666",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 73
            },
            {
              "entity_id": "T667",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 69,
              "end_idx": 70
            },
            {
              "entity_id": "T668",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 57,
              "end_idx": 59
            },
            {
              "entity_id": "T669",
              "entity": "稳定期",
              "entity_type": "Class",
              "start_idx": 20,
              "end_idx": 23
            },
            {
              "entity_id": "T670",
              "entity": "乳酸性",
              "entity_type": "Class",
              "start_idx": 45,
              "end_idx": 48
            }
          ],
          "relations": [
            {
              "relation_type": "Test_Disease",
              "relation_id": "R317",
              "head_entity_id": "T660",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R318",
              "head_entity_id": "T663",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R319",
              "head_entity_id": "T669",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R320",
              "head_entity_id": "T662",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R321",
              "head_entity_id": "T664",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R322",
              "head_entity_id": "T670",
              "tail_entity_id": "T665"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R323",
              "head_entity_id": "T668",
              "tail_entity_id": "T666"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R324",
              "head_entity_id": "T667",
              "tail_entity_id": "T666"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "69",
      "paragraph": "TZDs：可引起水钠潴留和血容量扩张，诱发或加重心力衰竭，故急性心力衰竭、NYHA心功能Ⅱ~IV级的慢性心力衰竭患者禁用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "TZDs：可引起水钠潴留和血容量扩张，诱发或加重心力衰竭，故急性心力衰竭、NYHA心功能Ⅱ~IV级的慢性心力衰竭患者禁用。",
          "start_idx": 0,
          "end_idx": 61,
          "entities": [
            {
              "entity_id": "T671",
              "entity": "TZDs",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T672",
              "entity": "水钠潴留",
              "entity_type": "ADE",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T673",
              "entity": "血容量扩张",
              "entity_type": "ADE",
              "start_idx": 13,
              "end_idx": 18
            },
            {
              "entity_id": "T674",
              "entity": "急性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 36
            },
            {
              "entity_id": "T675",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 30,
              "end_idx": 32
            },
            {
              "entity_id": "T676",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 32,
              "end_idx": 33
            },
            {
              "entity_id": "T677",
              "entity": "NYHA心功能Ⅱ~IV级",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 49
            },
            {
              "entity_id": "T678",
              "entity": "Ⅱ~IV级",
              "entity_type": "Class",
              "start_idx": 44,
              "end_idx": 49
            },
            {
              "entity_id": "T679",
              "entity": "慢性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 56
            },
            {
              "entity_id": "T680",
              "entity": "慢性",
              "entity_type": "Class",
              "start_idx": 50,
              "end_idx": 52
            },
            {
              "entity_id": "T681",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 52,
              "end_idx": 53
            },
            {
              "entity_id": "T682",
              "entity": "诱发或加重心力衰竭",
              "entity_type": "ADE",
              "start_idx": 19,
              "end_idx": 28
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R325",
              "head_entity_id": "T672",
              "tail_entity_id": "T671"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R326",
              "head_entity_id": "T673",
              "tail_entity_id": "T671"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R327",
              "head_entity_id": "T682",
              "tail_entity_id": "T671"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R328",
              "head_entity_id": "T676",
              "tail_entity_id": "T674"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R329",
              "head_entity_id": "T675",
              "tail_entity_id": "T674"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R330",
              "head_entity_id": "T678",
              "tail_entity_id": "T677"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R331",
              "head_entity_id": "T680",
              "tail_entity_id": "T679"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R332",
              "head_entity_id": "T681",
              "tail_entity_id": "T679"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "70",
      "paragraph": "DPP-4抑制剂：SAVOR-TIMI53研究显示，对于伴有心血管事件病史或心血管危险因素的T2DM患者，沙格列汀可增加心力衰竭住院风险。EXAMINE研究事后分析显示，对于无心力衰竭病史、近期发生过ACS的T2DM患者，阿格列汀增加心力衰竭住院风险( HR 1.76，P=0.026)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "DPP-4抑制剂：SAVOR-TIMI53研究显示，对于伴有心血管事件病史或心血管危险因素的T2DM患者，沙格列汀可增加心力衰竭住院风险。EXAMINE研究事后分析显示，对于无心力衰竭病史、近期发生过ACS的T2DM患者，阿格列汀增加心力衰竭住院风险( HR 1.76，P=0.026)。",
          "start_idx": 0,
          "end_idx": 144,
          "entities": [
            {
              "entity_id": "T683",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 8
            },
            {
              "entity_id": "T684",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 35
            },
            {
              "entity_id": "T685",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 30,
              "end_idx": 33
            },
            {
              "entity_id": "T686",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 38,
              "end_idx": 41
            },
            {
              "entity_id": "T687",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 50
            },
            {
              "entity_id": "T688",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 46,
              "end_idx": 48
            },
            {
              "entity_id": "T689",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T690",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 60,
              "end_idx": 64
            },
            {
              "entity_id": "T691",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 60,
              "end_idx": 61
            },
            {
              "entity_id": "T692",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 92
            },
            {
              "entity_id": "T693",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 88,
              "end_idx": 89
            },
            {
              "entity_id": "T694",
              "entity": "ACS",
              "entity_type": "Disease",
              "start_idx": 100,
              "end_idx": 103
            },
            {
              "entity_id": "T695",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 104,
              "end_idx": 108
            },
            {
              "entity_id": "T696",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 104,
              "end_idx": 106
            },
            {
              "entity_id": "T697",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 115
            },
            {
              "entity_id": "T698",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 121
            },
            {
              "entity_id": "T699",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 117,
              "end_idx": 118
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R333",
              "head_entity_id": "T685",
              "tail_entity_id": "T684"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R334",
              "head_entity_id": "T686",
              "tail_entity_id": "T687"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R335",
              "head_entity_id": "T688",
              "tail_entity_id": "T687"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R336",
              "head_entity_id": "T689",
              "tail_entity_id": "T687"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R337",
              "head_entity_id": "T691",
              "tail_entity_id": "T690"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R338",
              "head_entity_id": "T693",
              "tail_entity_id": "T692"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R339",
              "head_entity_id": "T697",
              "tail_entity_id": "T694"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R340",
              "head_entity_id": "T696",
              "tail_entity_id": "T695"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R341",
              "head_entity_id": "T697",
              "tail_entity_id": "T695"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R342",
              "head_entity_id": "T699",
              "tail_entity_id": "T698"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "71",
      "paragraph": "2015年4月，美国FDA对沙格列汀和阿格列汀提出警示，要求在说明书中增加对心力衰竭风险的标示。TECOS研究显示，在有心血管病史的T2DM患者中，西格列汀不增加心力衰竭住院风险，维格列汀的相关研究证据尚不充分.。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2015年4月，美国FDA对沙格列汀和阿格列汀提出警示，要求在说明书中增加对心力衰竭风险的标示。TECOS研究显示，在有心血管病史的T2DM患者中，西格列汀不增加心力衰竭住院风险，维格列汀的相关研究证据尚不充分.。",
          "start_idx": 0,
          "end_idx": 107,
          "entities": [
            {
              "entity_id": "T700",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18
            },
            {
              "entity_id": "T701",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23
            },
            {
              "entity_id": "T702",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 42
            },
            {
              "entity_id": "T703",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 38,
              "end_idx": 39
            },
            {
              "entity_id": "T704",
              "entity": "心血管病",
              "entity_type": "Disease",
              "start_idx": 60,
              "end_idx": 64
            },
            {
              "entity_id": "T705",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 60,
              "end_idx": 63
            },
            {
              "entity_id": "T706",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 70
            },
            {
              "entity_id": "T707",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 66,
              "end_idx": 68
            },
            {
              "entity_id": "T708",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 78
            },
            {
              "entity_id": "T709",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 85
            },
            {
              "entity_id": "T710",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 81,
              "end_idx": 82
            },
            {
              "entity_id": "T711",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 94
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R343",
              "head_entity_id": "T700",
              "tail_entity_id": "T702"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R344",
              "head_entity_id": "T701",
              "tail_entity_id": "T702"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R345",
              "head_entity_id": "T703",
              "tail_entity_id": "T702"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R346",
              "head_entity_id": "T705",
              "tail_entity_id": "T704"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R347",
              "head_entity_id": "T707",
              "tail_entity_id": "T706"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R348",
              "head_entity_id": "T708",
              "tail_entity_id": "T706"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R349",
              "head_entity_id": "T711",
              "tail_entity_id": "T706"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R350",
              "head_entity_id": "T710",
              "tail_entity_id": "T709"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "72",
      "paragraph": "GLP-1受体激动剂：LEADER和ELIXA研究显示，在心血管事件高危的T2DM患者中利拉鲁肽和利司那肽治疗不增加心力衰竭住院风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "GLP-1受体激动剂：LEADER和ELIXA研究显示，在心血管事件高危的T2DM患者中利拉鲁肽和利司那肽治疗不增加心力衰竭住院风险。",
          "start_idx": 0,
          "end_idx": 67,
          "entities": [
            {
              "entity_id": "T712",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 10
            },
            {
              "entity_id": "T713",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34
            },
            {
              "entity_id": "T714",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 29,
              "end_idx": 32
            },
            {
              "entity_id": "T715",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 41
            },
            {
              "entity_id": "T716",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 37,
              "end_idx": 39
            },
            {
              "entity_id": "T717",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 48
            },
            {
              "entity_id": "T718",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53
            },
            {
              "entity_id": "T719",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 62
            },
            {
              "entity_id": "T720",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 58,
              "end_idx": 59
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R351",
              "head_entity_id": "T714",
              "tail_entity_id": "T713"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R352",
              "head_entity_id": "T716",
              "tail_entity_id": "T715"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R353",
              "head_entity_id": "T717",
              "tail_entity_id": "T715"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R354",
              "head_entity_id": "T718",
              "tail_entity_id": "T715"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R355",
              "head_entity_id": "T720",
              "tail_entity_id": "T719"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "73",
      "paragraph": "SGLT-2抑制剂：EMPA-REG OUTCOME研究显示，在伴有心血管疾病的T2DM患者中，恩格列净可降低心力衰竭住院风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂：EMPA-REG OUTCOME研究显示，在伴有心血管疾病的T2DM患者中，恩格列净可降低心力衰竭住院风险。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T721",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 9
            },
            {
              "entity_id": "T722",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 39
            },
            {
              "entity_id": "T723",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 34,
              "end_idx": 37
            },
            {
              "entity_id": "T724",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 44
            },
            {
              "entity_id": "T725",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 40,
              "end_idx": 42
            },
            {
              "entity_id": "T726",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 52
            },
            {
              "entity_id": "T727",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 55,
              "end_idx": 59
            },
            {
              "entity_id": "T728",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 55,
              "end_idx": 56
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R356",
              "head_entity_id": "T723",
              "tail_entity_id": "T722"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R357",
              "head_entity_id": "T725",
              "tail_entity_id": "T724"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R358",
              "head_entity_id": "T726",
              "tail_entity_id": "T724"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R359",
              "head_entity_id": "T728",
              "tail_entity_id": "T727"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "74",
      "paragraph": "胰岛素：胰岛素治疗不增加心力衰竭患者的死亡风险。ORIGIN研究显示，在有心血管高危因素的糖代谢异常患者中，与二甲双胍或SUs相比，甘精膝岛素治疗不增加心力衰竭住院风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "胰岛素：胰岛素治疗不增加心力衰竭患者的死亡风险。ORIGIN研究显示，在有心血管高危因素的糖代谢异常患者中，与二甲双胍或SUs相比，甘精膝岛素治疗不增加心力衰竭住院风险。",
          "start_idx": 0,
          "end_idx": 85,
          "entities": [
            {
              "entity_id": "T729",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 3
            },
            {
              "entity_id": "T730",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7
            },
            {
              "entity_id": "T731",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 16
            },
            {
              "entity_id": "T732",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 13
            },
            {
              "entity_id": "T733",
              "entity": "糖代谢异常",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 50
            },
            {
              "entity_id": "T734",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 59
            },
            {
              "entity_id": "T735",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 63
            },
            {
              "entity_id": "T736",
              "entity": "甘精膝岛素",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 71
            },
            {
              "entity_id": "T737",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 76,
              "end_idx": 80
            },
            {
              "entity_id": "T738",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 76,
              "end_idx": 77
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R360",
              "head_entity_id": "T732",
              "tail_entity_id": "T731"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R361",
              "head_entity_id": "T738",
              "tail_entity_id": "T737"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "75",
      "paragraph": "其他降糖药物在心力衰竭患者中应用的安全性尚待进一步评估。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "其他降糖药物在心力衰竭患者中应用的安全性尚待进一步评估。",
          "start_idx": 0,
          "end_idx": 28,
          "entities": [
            {
              "entity_id": "T739",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 11
            },
            {
              "entity_id": "T740",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 8
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R362",
              "head_entity_id": "T740",
              "tail_entity_id": "T739"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "76",
      "paragraph": "3.低血糖",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.低血糖",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [
            {
              "entity_id": "T741",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "77",
      "paragraph": "低血糖对心血管系统具有显著的不良影响.其短期风险包括诱发心律失常、心血管事件，长期风险为认知障碍和痴呆，严重低血糖甚至可导致患者猝死。因此，对于合并ASCVD的T2DM患者，在降糖治疗过程中尤其应尽量避免出现低血糖。胰岛素和胰岛素促泌剂均可引起低血糖，与SUs相比，格列奈类药物的低血糖风险相对较低。二甲双胍、a-糖苷酶抑制剂、TZDs、GLP-1受体激动剂、DPP-4抑制剂以及SGLT-2抑制剂单独使用时通常不会导致低血糖，在接受降糖治疗的患者中，一旦发生低血糖，应迅速补充葡萄糖或含糖食物，以使血糖水平恢复正常，并及时调整降糖治疗方案。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "低血糖对心血管系统具有显著的不良影响.其短期风险包括诱发心律失常、心血管事件，长期风险为认知障碍和痴呆，严重低血糖甚至可导致患者猝死。因此，对于合并ASCVD的T2DM患者，在降糖治疗过程中尤其应尽量避免出现低血糖。胰岛素和胰岛素促泌剂均可引起低血糖，与SUs相比，格列奈类药物的低血糖风险相对较低。二甲双胍、a-糖苷酶抑制剂、TZDs、GLP-1受体激动剂、DPP-4抑制剂以及SGLT-2抑制剂单独使用时通常不会导致低血糖，在接受降糖治疗的患者中，一旦发生低血糖，应迅速补充葡萄糖或含糖食物，以使血糖水平恢复正常，并及时调整降糖治疗方案。",
          "start_idx": 0,
          "end_idx": 271,
          "entities": [
            {
              "entity_id": "T742",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3
            },
            {
              "entity_id": "T743",
              "entity": "心血管系统",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T744",
              "entity": "心律失常",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 32
            },
            {
              "entity_id": "T745",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38
            },
            {
              "entity_id": "T746",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 33,
              "end_idx": 36
            },
            {
              "entity_id": "T747",
              "entity": "认知障碍",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 48
            },
            {
              "entity_id": "T748",
              "entity": "痴呆",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 51
            },
            {
              "entity_id": "T749",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 57
            },
            {
              "entity_id": "T750",
              "entity": "猝死",
              "entity_type": "Disease",
              "start_idx": 64,
              "end_idx": 66
            },
            {
              "entity_id": "T751",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 79
            },
            {
              "entity_id": "T752",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 80,
              "end_idx": 84
            },
            {
              "entity_id": "T753",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 80,
              "end_idx": 82
            },
            {
              "entity_id": "T754",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 104,
              "end_idx": 107
            },
            {
              "entity_id": "T755",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 108,
              "end_idx": 111
            },
            {
              "entity_id": "T756",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 112,
              "end_idx": 118
            },
            {
              "entity_id": "T757",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 122,
              "end_idx": 125
            },
            {
              "entity_id": "T758",
              "entity": "SUs",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 130
            },
            {
              "entity_id": "T759",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 133,
              "end_idx": 139
            },
            {
              "entity_id": "T760",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 140,
              "end_idx": 143
            },
            {
              "entity_id": "T761",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 154
            },
            {
              "entity_id": "T762",
              "entity": "a-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 155,
              "end_idx": 163
            },
            {
              "entity_id": "T763",
              "entity": "TZDs",
              "entity_type": "Drug",
              "start_idx": 164,
              "end_idx": 168
            },
            {
              "entity_id": "T764",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 179
            },
            {
              "entity_id": "T765",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 180,
              "end_idx": 188
            },
            {
              "entity_id": "T766",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 199
            },
            {
              "entity_id": "T767",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 210,
              "end_idx": 213
            },
            {
              "entity_id": "T768",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 230,
              "end_idx": 233
            },
            {
              "entity_id": "T769",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 250,
              "end_idx": 252
            },
            {
              "entity_id": "T770",
              "entity": "恢复正常",
              "entity_type": "Test_Value",
              "start_idx": 254,
              "end_idx": 258
            },
            {
              "entity_id": "T771",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 239,
              "end_idx": 242
            },
            {
              "entity_id": "T772",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 52,
              "end_idx": 54
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R363",
              "head_entity_id": "T743",
              "tail_entity_id": "T742"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R364",
              "head_entity_id": "T746",
              "tail_entity_id": "T745"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R365",
              "head_entity_id": "T753",
              "tail_entity_id": "T752"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R366",
              "head_entity_id": "T757",
              "tail_entity_id": "T755"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R367",
              "head_entity_id": "T757",
              "tail_entity_id": "T756"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R368",
              "head_entity_id": "T760",
              "tail_entity_id": "T758"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R369",
              "head_entity_id": "T760",
              "tail_entity_id": "T759"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R370",
              "head_entity_id": "T767",
              "tail_entity_id": "T761"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R371",
              "head_entity_id": "T767",
              "tail_entity_id": "T762"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R372",
              "head_entity_id": "T767",
              "tail_entity_id": "T763"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R373",
              "head_entity_id": "T767",
              "tail_entity_id": "T764"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R374",
              "head_entity_id": "T767",
              "tail_entity_id": "T765"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R375",
              "head_entity_id": "T767",
              "tail_entity_id": "T766"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "78",
      "paragraph": "4.肾功能不全",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.肾功能不全",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [
            {
              "entity_id": "T773",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T774",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R376",
              "head_entity_id": "T774",
              "tail_entity_id": "T773"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "79",
      "paragraph": "T2DM和ASCVD患者常合并CKD。当患者存在肾功能不全[eGFR<60ml/(min.1.73m2)]时，大多数非胰岛素降糖药物的药代动力学会发生",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "T2DM和ASCVD患者常合并CKD。当患者存在肾功能不全[eGFR<60ml/(min.1.73m2)]时，大多数非胰岛素降糖药物的药代动力学会发生",
          "start_idx": 0,
          "end_idx": 75,
          "entities": [
            {
              "entity_id": "T775",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T776",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 0,
              "end_idx": 2
            },
            {
              "entity_id": "T777",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10
            },
            {
              "entity_id": "T778",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 18
            },
            {
              "entity_id": "T779",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29
            },
            {
              "entity_id": "T780",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 24,
              "end_idx": 25
            },
            {
              "entity_id": "T781",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 34
            },
            {
              "entity_id": "T782",
              "entity": "<60ml/(min.1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 34,
              "end_idx": 51
            },
            {
              "entity_id": "T783",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 62
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R377",
              "head_entity_id": "T776",
              "tail_entity_id": "T775"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R378",
              "head_entity_id": "T780",
              "tail_entity_id": "T779"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R379",
              "head_entity_id": "T781",
              "tail_entity_id": "T779"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "80",
      "paragraph": "改变。因此，对于合并CKD的患者.降糖药物的选择应基于药物的药代动力学特征和患者肾功能状态进行综合判断，以确保在有效降糖的同时不增加低血糖风险，并避免诱发乳酸性酸中毒.。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "改变。",
          "start_idx": 0,
          "end_idx": 3,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "因此，对于合并CKD的患者.降糖药物的选择应基于药物的药代动力学特征和患者肾功能状态进行综合判断，以确保在有效降糖的同时不增加低血糖风险，并避免诱发乳酸性酸中毒.。",
          "start_idx": 3,
          "end_idx": 85,
          "entities": [
            {
              "entity_id": "T784",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10
            },
            {
              "entity_id": "T785",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 63,
              "end_idx": 66
            },
            {
              "entity_id": "T786",
              "entity": "乳酸性酸中毒",
              "entity_type": "ADE",
              "start_idx": 74,
              "end_idx": 80
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "81",
      "paragraph": "瑞格列奈和利格列汀在CKD1~5期全程均可使用，且无需调整剂量。其他非胰岛素降糖药的使用均可因肾功能不全的不同程度而受到一定的影响。二甲双胍在CKD3a期[eGFR45~59ml/(min.1.73m2)]时应减量，在CKD3b期[eGFR30--45ml/(min.1.73m2)]时证据相对有限，谨慎观察下减量使用，在CKD4期[eGFR<30ml/(min.1.73m2)]时禁用。基于LEADER研究和LIRA-RENAL研究的数据.推荐利拉鲁肽可用于CKD1~3期，从CKD4期开始禁用。根据美国FDA批准的药品说明书，恩格列净可用于CKD1~3a期，从3b期开始不推荐使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "瑞格列奈和利格列汀在CKD1~5期全程均可使用，且无需调整剂量。其他非胰岛素降糖药的使用均可因肾功能不全的不同程度而受到一定的影响。二甲双胍在CKD3a期[eGFR45~59ml/(min.1.73m2)]时应减量，在CKD3b期[eGFR30--45ml/(min.1.73m2)]时证据相对有限，谨慎观察下减量使用，在CKD4期[eGFR<30ml/(min.1.73m2)]时禁用。基于LEADER研究和LIRA-RENAL研究的数据.推荐利拉鲁肽可用于CKD1~3期，从CKD4期开始禁用。根据美国FDA批准的药品说明书，恩格列净可用于CKD1~3a期，从3b期开始不推荐使用。",
          "start_idx": 0,
          "end_idx": 293,
          "entities": [
            {
              "entity_id": "T787",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T788",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9
            },
            {
              "entity_id": "T789",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 13
            },
            {
              "entity_id": "T790",
              "entity": "1~5期",
              "entity_type": "Class",
              "start_idx": 13,
              "end_idx": 17
            },
            {
              "entity_id": "T791",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 38
            },
            {
              "entity_id": "T792",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 52
            },
            {
              "entity_id": "T793",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 47,
              "end_idx": 48
            },
            {
              "entity_id": "T794",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 66,
              "end_idx": 70
            },
            {
              "entity_id": "T795",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 71,
              "end_idx": 74
            },
            {
              "entity_id": "T796",
              "entity": "3a期",
              "entity_type": "Class",
              "start_idx": 74,
              "end_idx": 77
            },
            {
              "entity_id": "T797",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 78,
              "end_idx": 82
            },
            {
              "entity_id": "T798",
              "entity": "45~59ml/(min.1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 82,
              "end_idx": 101
            },
            {
              "entity_id": "T799",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 109,
              "end_idx": 112
            },
            {
              "entity_id": "T800",
              "entity": "3b期",
              "entity_type": "Class",
              "start_idx": 112,
              "end_idx": 115
            },
            {
              "entity_id": "T801",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 116,
              "end_idx": 120
            },
            {
              "entity_id": "T802",
              "entity": "30--45ml/(min.1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 120,
              "end_idx": 140
            },
            {
              "entity_id": "T803",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 161,
              "end_idx": 164
            },
            {
              "entity_id": "T804",
              "entity": "4期",
              "entity_type": "Class",
              "start_idx": 164,
              "end_idx": 166
            },
            {
              "entity_id": "T805",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 167,
              "end_idx": 171
            },
            {
              "entity_id": "T806",
              "entity": "<30ml/(min.1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 171,
              "end_idx": 188
            },
            {
              "entity_id": "T807",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 223,
              "end_idx": 227
            },
            {
              "entity_id": "T808",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 230,
              "end_idx": 233
            },
            {
              "entity_id": "T809",
              "entity": "1~3期",
              "entity_type": "Class",
              "start_idx": 233,
              "end_idx": 237
            },
            {
              "entity_id": "T810",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 239,
              "end_idx": 242
            },
            {
              "entity_id": "T811",
              "entity": "4期",
              "entity_type": "Class",
              "start_idx": 242,
              "end_idx": 244
            },
            {
              "entity_id": "T812",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 265,
              "end_idx": 269
            },
            {
              "entity_id": "T813",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 272,
              "end_idx": 275
            },
            {
              "entity_id": "T814",
              "entity": "1~3a期",
              "entity_type": "Class",
              "start_idx": 275,
              "end_idx": 280
            },
            {
              "entity_id": "T815",
              "entity": "3b期",
              "entity_type": "Class",
              "start_idx": 282,
              "end_idx": 285
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R380",
              "head_entity_id": "T787",
              "tail_entity_id": "T789"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R381",
              "head_entity_id": "T788",
              "tail_entity_id": "T789"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R382",
              "head_entity_id": "T790",
              "tail_entity_id": "T789"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R383",
              "head_entity_id": "T793",
              "tail_entity_id": "T792"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R384",
              "head_entity_id": "T794",
              "tail_entity_id": "T795"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R385",
              "head_entity_id": "T796",
              "tail_entity_id": "T795"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R386",
              "head_entity_id": "T797",
              "tail_entity_id": "T795"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R387",
              "head_entity_id": "T801",
              "tail_entity_id": "T799"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R388",
              "head_entity_id": "T800",
              "tail_entity_id": "T799"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R389",
              "head_entity_id": "T805",
              "tail_entity_id": "T803"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R390",
              "head_entity_id": "T804",
              "tail_entity_id": "T803"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R391",
              "head_entity_id": "T807",
              "tail_entity_id": "T808"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R392",
              "head_entity_id": "T809",
              "tail_entity_id": "T808"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R393",
              "head_entity_id": "T811",
              "tail_entity_id": "T810"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R394",
              "head_entity_id": "T812",
              "tail_entity_id": "T813"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R395",
              "head_entity_id": "T814",
              "tail_entity_id": "T813"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R396",
              "head_entity_id": "T815",
              "tail_entity_id": "T813"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "82",
      "paragraph": "在CVOT中，包括肾脏不良事件在内的微血管事件通常作为研究的次要终点。在LEADER研究中，24.7%的患者基线时合并CKD3期或以上，利拉鲁肽可使肾脏事件复合终点(包括新发大量蛋白尿、Scr倍增、终末期肾病或肾病导致的死亡)的风险显著降低22%(P=0.003)。在EMPA-REGOUTCOME研究中，25.9%的患者基线时伴有CKD3期，恩格列净可使肾脏事件复合终点(Scr倍增、起始肾脏替代治疗或因肾病死亡)的风险显著降低46%(P<0.001)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "在CVOT中，包括肾脏不良事件在内的微血管事件通常作为研究的次要终点。在LEADER研究中，24.7%的患者基线时合并CKD3期或以上，利拉鲁肽可使肾脏事件复合终点(包括新发大量蛋白尿、Scr倍增、终末期肾病或肾病导致的死亡)的风险显著降低22%(P=0.003)。在EMPA-REGOUTCOME研究中，25.9%的患者基线时伴有CKD3期，恩格列净可使肾脏事件复合终点(Scr倍增、起始肾脏替代治疗或因肾病死亡)的风险显著降低46%(P<0.001)。",
          "start_idx": 0,
          "end_idx": 228,
          "entities": [
            {
              "entity_id": "T816",
              "entity": "肾脏不良事件",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 15
            },
            {
              "entity_id": "T817",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 9,
              "end_idx": 11
            },
            {
              "entity_id": "T818",
              "entity": "微血管事件",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23
            },
            {
              "entity_id": "T819",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 18,
              "end_idx": 21
            },
            {
              "entity_id": "T820",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 62
            },
            {
              "entity_id": "T821",
              "entity": "3期",
              "entity_type": "Class",
              "start_idx": 62,
              "end_idx": 64
            },
            {
              "entity_id": "T822",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 72
            },
            {
              "entity_id": "T823",
              "entity": "肾脏事件",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 78
            },
            {
              "entity_id": "T824",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 74,
              "end_idx": 76
            },
            {
              "entity_id": "T825",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 92
            },
            {
              "entity_id": "T826",
              "entity": "大量",
              "entity_type": "Level",
              "start_idx": 87,
              "end_idx": 89
            },
            {
              "entity_id": "T827",
              "entity": "Scr",
              "entity_type": "Test_items",
              "start_idx": 93,
              "end_idx": 96
            },
            {
              "entity_id": "T828",
              "entity": "倍增",
              "entity_type": "Test_Value",
              "start_idx": 96,
              "end_idx": 98
            },
            {
              "entity_id": "T829",
              "entity": "终末期肾病",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 104
            },
            {
              "entity_id": "T830",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 99,
              "end_idx": 102
            },
            {
              "entity_id": "T831",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 102,
              "end_idx": 103
            },
            {
              "entity_id": "T832",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 107
            },
            {
              "entity_id": "T833",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 105,
              "end_idx": 106
            },
            {
              "entity_id": "T834",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 166,
              "end_idx": 169
            },
            {
              "entity_id": "T835",
              "entity": "3期",
              "entity_type": "Class",
              "start_idx": 169,
              "end_idx": 171
            },
            {
              "entity_id": "T836",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 172,
              "end_idx": 176
            },
            {
              "entity_id": "T837",
              "entity": "肾脏事件",
              "entity_type": "Disease",
              "start_idx": 178,
              "end_idx": 182
            },
            {
              "entity_id": "T838",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 178,
              "end_idx": 180
            },
            {
              "entity_id": "T839",
              "entity": "Scr",
              "entity_type": "Test_items",
              "start_idx": 187,
              "end_idx": 190
            },
            {
              "entity_id": "T840",
              "entity": "倍增",
              "entity_type": "Test_Value",
              "start_idx": 190,
              "end_idx": 192
            },
            {
              "entity_id": "T841",
              "entity": "起始肾脏替代治疗",
              "entity_type": "Operation",
              "start_idx": 193,
              "end_idx": 201
            },
            {
              "entity_id": "T842",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 203,
              "end_idx": 205
            },
            {
              "entity_id": "T843",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 203,
              "end_idx": 204
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R397",
              "head_entity_id": "T817",
              "tail_entity_id": "T816"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R398",
              "head_entity_id": "T819",
              "tail_entity_id": "T818"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R399",
              "head_entity_id": "T821",
              "tail_entity_id": "T820"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R400",
              "head_entity_id": "T822",
              "tail_entity_id": "T820"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R401",
              "head_entity_id": "T827",
              "tail_entity_id": "T820"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R402",
              "head_entity_id": "T824",
              "tail_entity_id": "T823"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R403",
              "head_entity_id": "T830",
              "tail_entity_id": "T829"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R404",
              "head_entity_id": "T831",
              "tail_entity_id": "T829"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R405",
              "head_entity_id": "T833",
              "tail_entity_id": "T832"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R406",
              "head_entity_id": "T835",
              "tail_entity_id": "T834"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R407",
              "head_entity_id": "T836",
              "tail_entity_id": "T834"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R408",
              "head_entity_id": "T839",
              "tail_entity_id": "T834"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R409",
              "head_entity_id": "T838",
              "tail_entity_id": "T837"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R410",
              "head_entity_id": "T843",
              "tail_entity_id": "T842"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "83",
      "paragraph": "2016年6月，美国FDA修改坎格列净和达格列净的药物说明书，新增急性肾损伤风险的标签警示信息，建议处方这两种药物之前全面考虑增加急性肾损伤风险的各种因素，并在服药期间监测肾功能的动态变化。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2016年6月，美国FDA修改坎格列净和达格列净的药物说明书，新增急性肾损伤风险的标签警示信息，建议处方这两种药物之前全面考虑增加急性肾损伤风险的各种因素，并在服药期间监测肾功能的动态变化。",
          "start_idx": 0,
          "end_idx": 95,
          "entities": [
            {
              "entity_id": "T844",
              "entity": "坎格列净",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19
            },
            {
              "entity_id": "T845",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 24
            },
            {
              "entity_id": "T846",
              "entity": "急性肾损伤",
              "entity_type": "ADE",
              "start_idx": 33,
              "end_idx": 38
            },
            {
              "entity_id": "T847",
              "entity": "急性肾损伤",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 70
            },
            {
              "entity_id": "T848",
              "entity": "急性",
              "entity_type": "Class",
              "start_idx": 65,
              "end_idx": 67
            },
            {
              "entity_id": "T849",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 67,
              "end_idx": 68
            },
            {
              "entity_id": "T850",
              "entity": "肾功能",
              "entity_type": "Test",
              "start_idx": 86,
              "end_idx": 89
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R411",
              "head_entity_id": "T846",
              "tail_entity_id": "T844"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R412",
              "head_entity_id": "T846",
              "tail_entity_id": "T845"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R413",
              "head_entity_id": "T849",
              "tail_entity_id": "T847"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R414",
              "head_entity_id": "T848",
              "tail_entity_id": "T847"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "84",
      "paragraph": "表4总结了T2DM合并ASCVD患者降糖药物使用应着重关注的主要安全性问题，其中包括药物的心血管效应、低血糖风险、对体重的影响、在心力衰竭或肝肾功能不全等特殊患者中应用的注意事项。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "表4总结了T2DM合并ASCVD患者降糖药物使用应着重关注的主要安全性问题，其中包括药物的心血管效应、低血糖风险、对体重的影响、在心力衰竭或肝肾功能不全等特殊患者中应用的注意事项。",
          "start_idx": 0,
          "end_idx": 90,
          "entities": [
            {
              "entity_id": "T851",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 9
            },
            {
              "entity_id": "T852",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 5,
              "end_idx": 7
            },
            {
              "entity_id": "T853",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16
            },
            {
              "entity_id": "T854",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 69
            },
            {
              "entity_id": "T855",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 65,
              "end_idx": 66
            },
            {
              "entity_id": "T856",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 70,
              "end_idx": 76
            },
            {
              "entity_id": "T857",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 70,
              "end_idx": 71
            },
            {
              "entity_id": "T858",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 71,
              "end_idx": 72
            },
            {
              "entity_id": "T859",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 51,
              "end_idx": 54
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R415",
              "head_entity_id": "T852",
              "tail_entity_id": "T851"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R416",
              "head_entity_id": "T855",
              "tail_entity_id": "T854"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R417",
              "head_entity_id": "T857",
              "tail_entity_id": "T856"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R418",
              "head_entity_id": "T858",
              "tail_entity_id": "T856"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "85",
      "paragraph": "五、结语与展望",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "五、结语与展望",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "86",
      "paragraph": "对于T2DM合并ASCVD患者，应采取综合管理策略，全面控制高血糖、高血压、血脂异常、超重或肥胖等多重心血管危险因素。在血糖管理方面，临床医师应充分考虑降糖药物的疗效与安全性之间的平衡，并且全面了解常用降糖药物的心血管安全性，这样才能熟练掌握其应用原则。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于T2DM合并ASCVD患者，应采取综合管理策略，全面控制高血糖、高血压、血脂异常、超重或肥胖等多重心血管危险因素。在血糖管理方面，临床医师应充分考虑降糖药物的疗效与安全性之间的平衡，并且全面了解常用降糖药物的心血管安全性，这样才能熟练掌握其应用原则。",
          "start_idx": 0,
          "end_idx": 127,
          "entities": [
            {
              "entity_id": "T860",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T861",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4
            },
            {
              "entity_id": "T862",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 13
            },
            {
              "entity_id": "T863",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 33
            },
            {
              "entity_id": "T864",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 37
            },
            {
              "entity_id": "T865",
              "entity": "血脂异常",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 42
            },
            {
              "entity_id": "T866",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 45
            },
            {
              "entity_id": "T867",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 48
            },
            {
              "entity_id": "T868",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 51,
              "end_idx": 54
            },
            {
              "entity_id": "T869",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 62
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R419",
              "head_entity_id": "T861",
              "tail_entity_id": "T860"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R420",
              "head_entity_id": "T868",
              "tail_entity_id": "T860"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R421",
              "head_entity_id": "T868",
              "tail_entity_id": "T862"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "87",
      "paragraph": "随着CVOT的广泛开展，其研究结果将陆续公布。最新公布的SUSTAIN-6研究显示，新型长效GLP-1受体激动剂索马鲁肽(semaglutide，尚未被批准上市)同样也可显著降低心血管事件风险。因此，有理由相信未来将会出现越来越多可为T2DM患者带来心血管保护作用的降糖药物，这将推动T2DM(特别是合并ASCVD)患者的治疗策略和理念发生巨大的变革。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "随着CVOT的广泛开展，其研究结果将陆续公布。最新公布的SUSTAIN-6研究显示，新型长效GLP-1受体激动剂索马鲁肽(semaglutide，尚未被批准上市)同样也可显著降低心血管事件风险。因此，有理由相信未来将会出现越来越多可为T2DM患者带来心血管保护作用的降糖药物，这将推动T2DM(特别是合并ASCVD)患者的治疗策略和理念发生巨大的变革。",
          "start_idx": 0,
          "end_idx": 176,
          "entities": [
            {
              "entity_id": "T870",
              "entity": "长效GLP-1受体激动剂索马鲁肽(semaglutide，尚未被批准上市)",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 81
            },
            {
              "entity_id": "T871",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 94
            },
            {
              "entity_id": "T872",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 89,
              "end_idx": 92
            },
            {
              "entity_id": "T873",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 121
            },
            {
              "entity_id": "T874",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 117,
              "end_idx": 119
            },
            {
              "entity_id": "T875",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 146
            },
            {
              "entity_id": "T876",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 142,
              "end_idx": 144
            },
            {
              "entity_id": "T877",
              "entity": "ASCVD",
              "entity_type": "Disease",
              "start_idx": 152,
              "end_idx": 157
            },
            {
              "entity_id": "T878",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 125,
              "end_idx": 128
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R422",
              "head_entity_id": "T872",
              "tail_entity_id": "T871"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R423",
              "head_entity_id": "T874",
              "tail_entity_id": "T873"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R424",
              "head_entity_id": "T878",
              "tail_entity_id": "T873"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R425",
              "head_entity_id": "T876",
              "tail_entity_id": "T875"
            }
          ]
        }
      ]
    }
  ]
}